Download PDF

Clinical Trial Results:
An Open-label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination with Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors

Summary
EudraCT number	2012-003126-25
Trial protocol	GB
Global end of trial date	11 Mar 2020

Results information
Results version number	v1(current)
This version publication date	21 Mar 2021
First version publication date	21 Mar 2021
Other versions

Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information

Collapse all Expand all

Trial information

Top of page

Sponsor protocol code

MS201923-0001

ISRCTN number

US NCT number

NCT02157792

WHO universal trial number (UTN)

Sponsor organisation name

Merck KGaA, Darmstadt, Germany

Sponsor organisation address

Frankfurter Strasse 250, Darmstadt, Germany, 64293

Public contact

Communication Centre, Merck KGaA, Darmstadt, Germany, +49 6151725200, service@merckgroup.com

Scientific contact

Communication Center, Merck KGaA, Darmstadt, Germany, +49 6151725200, service@merckgroup.com

Is trial part of an agreed paediatric investigation plan (PIP)

Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?

Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?

Analysis stage

Final

Date of interim/final analysis

11 Mar 2020

Is this the analysis of the primary completion data?

Global end of trial reached?

Yes

Global end of trial date

11 Mar 2020

Was the trial ended prematurely?

Main objective of the trial

The primary objective of this study is to evaluate the safety and tolerability of multiple ascending doses of intravenously administered M6620 in combination with gemcitabine, and in combination with cisplatin and gemcitabine, in subjects with advanced solid tumors.

Protection of trial subjects

Subject protection was ensured by following high medical and ethical standards in accordance with the principles laid down in the Declaration of Helsinki, and that are consistent with Good Clinical Practice and applicable regulations.

Background therapy

Evidence for comparator

Actual start date of recruitment

10 Dec 2012

Long term follow-up planned

Independent data monitoring committee (IDMC) involvement?

Number of subjects enrolled per country

Country: Number of subjects enrolled

United Kingdom: 118

Country: Number of subjects enrolled

United States: 79

Worldwide total number of subjects

197

EEA total number of subjects

Number of subjects enrolled per age group

In utero

Preterm newborn - gestational age < 37 wk

Newborns (0-27 days)

Infants and toddlers (28 days-23 months)

Children (2-11 years)

Adolescents (12-17 years)

Adults (18-64 years)

134

From 65 to 84 years

85 years and over

Subject disposition

Top of page

Recruitment details

Screening details

First subject signed informed consent: 10 Dec 2012, Last subject last visit: 11 Mar 2020.

Period 1 title

Overall Study (overall period)

Is this the baseline period?

Yes

Allocation method

Not applicable

Blinding used

Not blinded

Are arms mutually exclusive

Yes

Part A1: M6620 18 mg/m^2 + Gemcitabine 875 mg/m^2

Arm description

Subjects received intravenous infusion of M6620 at a initial dose of 18 milligrams per square meter (mg/m^2) approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine at a dose of 875 mg/m^2 on Days 1 and 8 of a 21-day cycle up to 61 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at a initial dose of 18 milligrams per square meter (mg/m^2) approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine.

Investigational medicinal product name

Gemcitabine

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of Gemcitabine at a dose of 875 mg/m^2 on Days 1 and 8 in combination with M6620.

Part A1: M6620 36 mg/m^2 + Gemcitabine 875 mg/m^2

Arm description

Subjects received intravenous infusion of M6620 at escalated dose of 36 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine at a dose of 875 mg/m^2 on Days 1 and 8 of a 21-day cycle up to 61 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at escalated dose of 36 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine.

Investigational medicinal product name

Gemcitabine

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of Gemcitabine at a dose of 875 mg/m^2 on Days 1 and 8 in combination with M6620.

Part A1: M6620 60 mg/m^2 + Gemcitabine 875 mg/m^2

Arm description

Subjects received intravenous infusion of M6620 at escalated dose of 60 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine at a dose of 875 mg/m^2 on Days 1 and 8 of a 21-day cycle up to 61 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at escalated dose of 60 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine.

Investigational medicinal product name

Gemcitabine

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of Gemcitabine at a dose of 875 mg/m^2 on Days 1 and 8 in combination with M6620.

Part A1: M6620 72 mg/m^2 + Gemcitabine 875 mg/m^2

Arm description

Subjects received intravenous infusion of M6620 at escalated dose of 72 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine at a dose of 875 mg/m^2 on Days 1 and 8 of a 21-day cycle up to 61 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at escalated dose of 72 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine.

Investigational medicinal product name

Gemcitabine

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of Gemcitabineat at a dose of 875 mg/m^2 on Days 1 and 8 in combination with M6620.

Part A1: M6620 90 mg/m^2 + Gemcitabine 500 mg/m^2

Arm description

Subjects received intravenous infusion of M6620 at escalated dose of 90 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine at a dose of 500 mg/m^2 on Days 1 and 8 of a 21-day cycle up to 61 weeks.

Arm type

Experimental

Investigational medicinal product name

Gemcitabine

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of Gemcitabine at a dose of 500 mg/m^2 on Days 1 and 8 in combination with M6620.

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at escalated dose of 90 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine.

Part A1: M6620 140 mg/m^2 + Gemcitabine 500 mg/m^2

Arm description

Subjects received intravenous infusion of M6620 at escalated dose of 140 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine at a dose of 500 mg/m^2 on Days 1 and 8 of a 21-day cycle up to 61 weeks.

Arm type

Experimental

Investigational medicinal product name

Gemcitabine

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of Gemcitabine at dose of 500 mg/m^2 on Days 1 and 8 in combination with M6620.

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at escalated dose of 140 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine.

Part A1: M6620 210 mg/m^2 + Gemcitabine 500 mg/m^2

Arm description

Subjects received intravenous infusion of M6620 at escalated dose of 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine at a dose of 500 mg/m^2 on Days 1 and 8 of a 21-day cycle up to 61 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at escalated dose of 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine.

Investigational medicinal product name

Gemcitabine

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of Gemcitabine at a dose of 500 mg/m^2 on Days 1 and 8 in combination with M6620.

Part A1: M6620 210 mg/m^2 + Gemcitabine 750 mg/m^2

Arm description

Subjects received intravenous infusion of M6620 at escalated dose of 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine at a dose of 750 mg/m^2 on Days 1 and 8 of a 21-day cycle up to 61 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at escalated dose of 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine.

Investigational medicinal product name

Gemcitabine

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of Gemcitabine at a dose of 750 mg/m^2 on Days 1 and 8 in combination with M6620.

Part A1: M6620 210 mg/m^2 + Gemcitabine 875 mg/m^2

Arm description

Subjects received intravenous infusion of M6620 at escalated dose of 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine at a dose of 875 mg/m^2 on Days 1 and 8 of a 21-day cycle up to 61 weeks.

Arm type

Experimental

Investigational medicinal product name

Gemcitabine

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of Gemcitabine at a dose of 875 mg/m^2 on Days 1 and 8 in combination with M6620.

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at escalated dose of 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine.

Part A1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2

Arm description

Subjects received intravenous infusion of M6620 at escalated dose of 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine at a dose of 1000 mg/m^2 on Days 1 and 8 of a 21-day cycle up to 61 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at escalated dose of 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine.

Investigational medicinal product name

Gemcitabine

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of Gemcitabine at a dose of 1000 mg/m^2 on Days 1 and 8 in combination with M6620.

Part A2: M6620 90 mg/m^2 + Gemcitabine + Cisplatin

Arm description

Subjects received intravenous infusion of M6620 at dose of 90 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine at a dose of 875 mg/m^2 on Days 1 and 8 and 60 mg/m^2 of Cisplatin on Day 1, of a 21-day cycle up to 41 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at dose of 90 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine and Cisplatin.

Investigational medicinal product name

Gemcitabine

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of Gemcitabine at a dose of 875 mg/m^2 on Days 1 and 8 in combination with M6620 and Cisplatin.

Investigational medicinal product name

Cisplatin

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of Cisplatin at a dose 60 mg/m^2 on Day 1 in combination with M6620 and Gemcitabine.

Part A2: M6620 120 mg/m^2 + Gemcitabine + Cisplatin

Arm description

Subjects received intravenous infusion of M6620 at dose of 120 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine at a dose of 875 mg/m^2 on Days 1 and 8 and 60 mg/m^2 of Cisplatin on Day 1, of a 21-day cycle up to 41 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at dose of 120 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine and Cisplatin.

Investigational medicinal product name

Cisplatin

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of Cisplatin at a dose of 60 mg/m^2 on Day 1 in combination with M6620 and Gemcitabine.

Investigational medicinal product name

Gemcitabine

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of Gemcitabine at a dose of 875 mg/m^2 on Days 1 and 8 n combination with M6620 and Cisplatin.

Part B1: M6620 140 mg/m^2

Arm description

Subjects received intravenous infusion of M6620 at dose of 140 mg/m^2 approximately for 24 hours later on Days 2 and 9 of a 21-day cycle up to 74 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at dose of 140 mg/m^2 approximately for 24 hours later on Days 2 and 9.

Part B1: M6620 90 mg/m^2 + Cisplatin 40 mg/m^2

Arm description

Subjects received intravenous infusion of M6620 at dose of 90 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with 40 mg/m^2 of Cisplatin on Day 1, of a 21-day cycle up to 74 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at dose of 90 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Cisplatin.

Investigational medicinal product name

Cisplatin

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of Cisplatin at a dose of 40 mg/m^2 of on Day 1 in combination with M6620.

Part B1: M6620 140 mg/m^2 + Cisplatin 40 mg/m^2

Arm description

Subjects received intravenous infusion of M6620 at dose of 140mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with 40 mg/m^2 of Cisplatin on Day 1 of a 21-day cycle up to 74 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at dose of 140mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Cisplatin.

Investigational medicinal product name

Cisplatin

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of 40 mg/m^2 of Cisplatin on Day 1 in combination with M6620.

Part B1: M6620 210 mg/m^2 + Cisplatin 40 mg/m^2

Arm description

Subjects received intravenous infusion of M6620 at dose of 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with 40 mg/m^2 of Cisplatin on Day 1 of a 21-day cycle up to 74 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at dose of 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Cisplatin.

Investigational medicinal product name

Cisplatin

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of Cisplatin at a dose of 40 mg/m^2 of on Day 1 in combination with M6620.

Part B1: M6620 210 mg/m^2 + Cisplatin 60 mg/m^2

Arm description

Subjects received intravenous infusion of M6620 at dose of 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with 60 mg/m^2 of Cisplatin on Day 1 of a 21-day cycle up to 74 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at dose of 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Cisplatin.

Investigational medicinal product name

Cisplatin

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of Cisplatin at a dose of 60 mg/m^2 of on Day 1 in combination with M6620.

Part B1: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2

Arm description

Subjects received intravenous infusion of M6620 at dose of 140 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with 75 mg/m^2 of Cisplatin on Day 1 of a 21-day cycle up to 74 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at dose of 140 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Cisplatin.

Investigational medicinal product name

Cisplatin

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of Cisplatin at a dose of 75 mg/m^2 on Day 1 in combination with M6620.

Part B1: M6620 210 mg/m^2 + Cisplatin 75 mg/m^2

Arm description

Subjects received intravenous infusion of M6620 at dose of 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with 75 mg/m^2 of Cisplatin on Day 1 of a 21-day cycle up to 74 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at dose of 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Cisplatin.

Investigational medicinal product name

Cisplatin

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of Cisplatin at a dose of 75 mg/m^2 of on Day 1 in combination with M6620.

Part B2: M6620 60 mg/m^2 + Irinotecan 180 mg/m^2

Arm description

Subjects received intravenous infusion of M6620 at a dose of 60 mg/m^2, in combination with irinotecan at a dose of 180 mg/m^2 (over 90 minutes) on Days 1 and 15 of a 28-day cycle up to 72 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at a dose of 60 mg/m^2, in combination with irinotecan.

Investigational medicinal product name

Irinotecan

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of irinotecan at a dose of 180 mg/m^2 (over 90 minutes) on Days 1 and 15 in combination with M6620.

Part B2: M6620 90 mg/m^2 + Irinotecan 180 mg/m^2

Arm description

Subjects received intravenous infusion of M6620 at a dose of 90 mg/m^2, in combination with irinotecan at a dose of 180 mg/m^2 (over 90 minutes) on Days 1 and 15 of a 28-day cycle up to 72 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects received intravenous infusion of M6620 at a dose of 90 mg/m^2, in combination with irinotecan.

Investigational medicinal product name

Irinotecan

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use, Intravenous use

Dosage and administration details

Subjects received intravenous infusion of irinotecan at a dose of 180 mg/m^2 (over 90 minutes) on Days 1 and 15 in combination with M6620.

Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2

Arm description

Subjects with advanced non-small cell lung cancer (NSCLC) received intravenous infusion of M6620 at a dose of 210 mg/m^2 on Days 2 and 9 in combination with Gemcitabine at a dose of 1000 mg/m^2 on Days 1 and 8 of a 21-day cycle up to 63 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects with advanced non-small cell lung cancer (NSCLC) received intravenous infusion of M6620 at a dose of 210 mg/m^2 on Days 2 and 9 in combination with Gemcitabine.

Investigational medicinal product name

Gemcitabine

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects with advanced non-small cell lung cancer (NSCLC) received intravenous infusion of Gemcitabine at a dose of 1000 mg/m^2 on Days 1 and 8 in combination with M6620.

Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2

Arm description

Subjects with advanced triple negative breast cancer (TNBC) received intravenous infusion of M6620 at a dose of 140 mg/m^2 on Days 2 and 9 in combination with Cisplatin at a dose of 75 mg/m^2 on Day 1 of a 21-day cycle up to 137 weeks.

Arm type

Experimental

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects with advanced triple negative breast cancer (TNBC) received intravenous infusion of M6620 at a dose of 140 mg/m^2 on Days 2 and 9 in combination with Cisplatin.

Investigational medicinal product name

Cisplatin

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects with advanced triple negative breast cancer (TNBC) received intravenous infusion of Cisplatin at a dose of 75 mg/m^2 on Day 1 in combination with M6620.

Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2

Arm description

Subjects with platinum-resistant advanced small cell lung cancer (SCLC) received intravenous infusion of M6620 at a dose of 140 mg/m^2 on Days 2 and 9 in combination with Cisplatin at a dose of 75 mg/m^2 on Day 1 of a 21-day cycle up to 27 weeks.

Arm type

Experimental

Investigational medicinal product name

Cisplatin

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects with platinum-resistant advanced small cell lung cancer (SCLC) received intravenous infusion of Cisplatin at a dose of 75 mg/m^2 on Day 1 in combination with M6620.

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects with platinum-resistant advanced small cell lung cancer (SCLC) received intravenous infusion of M6620 at a dose of 140 mg/m^2 on Days 2 and 9 in combination with Cisplatin.

Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL

Arm description

Subjects with platinum-resistant advanced SCLC received intravenous infusion of M6620 at a dose of 90 mg/m^2 on Days 2 and 9 in combination with carboplatin area under concentration-time curve (AUC) at a dose of 5 milligrams.minute per milliliter on Day 1 of a 21-day cycle up to 27 weeks.

Arm type

Experimental

Investigational medicinal product name

Carboplatin

Investigational medicinal product code

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects with platinum-resistant advanced SCLC received intravenous infusion of Carboplatin are under concentration-time curve (AUC) at a dose of 5 mg.min/mL on Day 1 in combination with M6620.

Investigational medicinal product name

M6620

Investigational medicinal product code

M6620

Other name

Pharmaceutical forms

Concentrate for solution for injection/infusion

Routes of administration

Intravenous use

Dosage and administration details

Subjects with platinum-resistant advanced SCLC received intravenous infusion of M6620 at a dose of 90 mg/m^2 on Days 2 and 9 in combination with Carboplatin.

Number of subjects in period 1	Part A1: M6620 18 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 36 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 60 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 72 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 90 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 140 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 750 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part A2: M6620 90 mg/m^2 + Gemcitabine + Cisplatin	Part A2: M6620 120 mg/m^2 + Gemcitabine + Cisplatin	Part B1: M6620 140 mg/m^2	Part B1: M6620 90 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 140 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 60 mg/m^2	Part B1: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 75 mg/m^2	Part B2: M6620 60 mg/m^2 + Irinotecan 180 mg/m^2	Part B2: M6620 90 mg/m^2 + Irinotecan 180 mg/m^2	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Started	3	3	4	7	6	8	3	3	7	6	6	2	1	3	3	4	10	7	3	5	3	38	47	2	13
Completed	3	3	4	7	6	8	3	3	7	6	6	2	1	3	3	4	10	7	3	5	3	38	47	2	13

Baseline characteristics

Top of page

Reporting group title

Part A1: M6620 18 mg/m^2 + Gemcitabine 875 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 36 mg/m^2 + Gemcitabine 875 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 60 mg/m^2 + Gemcitabine 875 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 72 mg/m^2 + Gemcitabine 875 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 90 mg/m^2 + Gemcitabine 500 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 140 mg/m^2 + Gemcitabine 500 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 210 mg/m^2 + Gemcitabine 500 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 210 mg/m^2 + Gemcitabine 750 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 210 mg/m^2 + Gemcitabine 875 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2

Reporting group description

Reporting group title

Part A2: M6620 90 mg/m^2 + Gemcitabine + Cisplatin

Reporting group description

Reporting group title

Part A2: M6620 120 mg/m^2 + Gemcitabine + Cisplatin

Reporting group description

Reporting group title

Part B1: M6620 140 mg/m^2

Reporting group description

Subjects received intravenous infusion of M6620 at dose of 140 mg/m^2 approximately for 24 hours later on Days 2 and 9 of a 21-day cycle up to 74 weeks.

Reporting group title

Part B1: M6620 90 mg/m^2 + Cisplatin 40 mg/m^2

Reporting group description

Reporting group title

Part B1: M6620 140 mg/m^2 + Cisplatin 40 mg/m^2

Reporting group description

Reporting group title

Part B1: M6620 210 mg/m^2 + Cisplatin 40 mg/m^2

Reporting group description

Reporting group title

Part B1: M6620 210 mg/m^2 + Cisplatin 60 mg/m^2

Reporting group description

Reporting group title

Part B1: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2

Reporting group description

Reporting group title

Part B1: M6620 210 mg/m^2 + Cisplatin 75 mg/m^2

Reporting group description

Reporting group title

Part B2: M6620 60 mg/m^2 + Irinotecan 180 mg/m^2

Reporting group description

Subjects received intravenous infusion of M6620 at a dose of 60 mg/m^2, in combination with irinotecan at a dose of 180 mg/m^2 (over 90 minutes) on Days 1 and 15 of a 28-day cycle up to 72 weeks.

Reporting group title

Part B2: M6620 90 mg/m^2 + Irinotecan 180 mg/m^2

Reporting group description

Subjects received intravenous infusion of M6620 at a dose of 90 mg/m^2, in combination with irinotecan at a dose of 180 mg/m^2 (over 90 minutes) on Days 1 and 15 of a 28-day cycle up to 72 weeks.

Reporting group title

Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2

Reporting group description

Reporting group title

Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2

Reporting group description

Reporting group title

Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2

Reporting group description

Reporting group title

Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL

Reporting group description

Reporting group values	Part A1: M6620 18 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 36 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 60 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 72 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 90 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 140 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 750 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part A2: M6620 90 mg/m^2 + Gemcitabine + Cisplatin	Part A2: M6620 120 mg/m^2 + Gemcitabine + Cisplatin	Part B1: M6620 140 mg/m^2	Part B1: M6620 90 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 140 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 60 mg/m^2	Part B1: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 75 mg/m^2	Part B2: M6620 60 mg/m^2 + Irinotecan 180 mg/m^2	Part B2: M6620 90 mg/m^2 + Irinotecan 180 mg/m^2	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL	Total
Number of subjects	3	3	4	7	6	8	3	3	7	6	6	2	1	3	3	4	10	7	3	5	3	38	47	2	13	197
Age Categorical
Units: subjects
<=18 years	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Between 18 and 65 years	3	2	3	5	3	6	3	2	3	3	4	2	1	2	0	3	4	5	1	4	2	22	43	2	6	134
>=65 years	0	1	1	2	3	2	0	1	4	3	2	0	0	1	3	1	6	2	2	1	1	16	4	0	7	63
Sex: Female, Male
Units: subjects
Female	2	0	1	4	3	2	2	2	3	3	3	1	1	2	1	1	5	6	1	3	1	18	47	2	8	122
Male	1	3	3	3	3	6	1	1	4	3	3	1	0	1	2	3	5	1	2	2	2	20	0	0	5	75
Race (NIH/OMB)
Units: Subjects
American Indian or Alaska Native	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Asian	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	1	0	0	5
Native Hawaiian or Other Pacific Islander	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Black or African American	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	2	0	2	6
White	3	2	4	7	6	8	3	3	7	6	6	2	1	3	2	3	8	7	3	3	3	34	41	2	11	178
More than one race	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	2
Unknown or Not Reported	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	3	0	0	6
Ethnicity (NIH/OMB)
Units: Subjects
Hispanic or Latino	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	3	3	4	0	0	15
Not Hispanic or Latino	3	3	4	7	5	8	3	3	7	6	6	2	1	3	3	4	10	7	3	0	0	32	41	1	13	175
Unknown or Not Reported	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	2	1	0	7

End points

Top of page

Reporting group title

Part A1: M6620 18 mg/m^2 + Gemcitabine 875 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 36 mg/m^2 + Gemcitabine 875 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 60 mg/m^2 + Gemcitabine 875 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 72 mg/m^2 + Gemcitabine 875 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 90 mg/m^2 + Gemcitabine 500 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 140 mg/m^2 + Gemcitabine 500 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 210 mg/m^2 + Gemcitabine 500 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 210 mg/m^2 + Gemcitabine 750 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 210 mg/m^2 + Gemcitabine 875 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2

Reporting group description

Reporting group title

Part A2: M6620 90 mg/m^2 + Gemcitabine + Cisplatin

Reporting group description

Reporting group title

Part A2: M6620 120 mg/m^2 + Gemcitabine + Cisplatin

Reporting group description

Reporting group title

Part B1: M6620 140 mg/m^2

Reporting group description

Subjects received intravenous infusion of M6620 at dose of 140 mg/m^2 approximately for 24 hours later on Days 2 and 9 of a 21-day cycle up to 74 weeks.

Reporting group title

Part B1: M6620 90 mg/m^2 + Cisplatin 40 mg/m^2

Reporting group description

Reporting group title

Part B1: M6620 140 mg/m^2 + Cisplatin 40 mg/m^2

Reporting group description

Reporting group title

Part B1: M6620 210 mg/m^2 + Cisplatin 40 mg/m^2

Reporting group description

Reporting group title

Part B1: M6620 210 mg/m^2 + Cisplatin 60 mg/m^2

Reporting group description

Reporting group title

Part B1: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2

Reporting group description

Reporting group title

Part B1: M6620 210 mg/m^2 + Cisplatin 75 mg/m^2

Reporting group description

Reporting group title

Part B2: M6620 60 mg/m^2 + Irinotecan 180 mg/m^2

Reporting group description

Subjects received intravenous infusion of M6620 at a dose of 60 mg/m^2, in combination with irinotecan at a dose of 180 mg/m^2 (over 90 minutes) on Days 1 and 15 of a 28-day cycle up to 72 weeks.

Reporting group title

Part B2: M6620 90 mg/m^2 + Irinotecan 180 mg/m^2

Reporting group description

Subjects received intravenous infusion of M6620 at a dose of 90 mg/m^2, in combination with irinotecan at a dose of 180 mg/m^2 (over 90 minutes) on Days 1 and 15 of a 28-day cycle up to 72 weeks.

Reporting group title

Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2

Reporting group description

Reporting group title

Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2

Reporting group description

Reporting group title

Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2

Reporting group description

Reporting group title

Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL

Reporting group description

Subject analysis set title

Part A1: All Subjects

Subject analysis set type

Safety analysis

Subject analysis set description

Subjects who received M6620 at a dose of 18, 36, 60, 72, 90, 140 or 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemicitabine at a dose of 875, 500, 750 or 1000 mg/m^2 on Days 1 and 8 of a 21-day cycle up to 61 weeks.

Subject analysis set title

Part A2: All Subjects

Subject analysis set type

Safety analysis

Subject analysis set description

Subjects who received M6620 at a dose of 90 or120 mg/m^2 in combination with Gemcitabine at a dose of 875 mg/m^2 on Days 1 and 8 and 60 mg/m^2 of Cisplatin on Day 1 of a 21-day cycle up to 41 weeks.

Subject analysis set title

Parts B1: All Subjects

Subject analysis set type

Safety analysis

Subject analysis set description

Subjects who received intravenous infusion of M6620 at dose of 140, 90 or 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Cisplatin at a dose 40, 60 or 75 mg/m^2 on Day 1 of a 21-day cycle up to 74 weeks.

Subject analysis set title

Part B2: All Subjects

Subject analysis set type

Safety analysis

Subject analysis set description

Subjects who received intravenous infusion of M6620 at a dose of 60 or 90 mg/m^2 in combination with irinotecan at a dose of 180 mg/m^2 (over 90 minutes) on Days 1 and 15 of a 28-day cycle up to 72 weeks.

Subject analysis set title

Part A1: M6620 120 mg/m^2 and Gemcitabine

Subject analysis set type

Full analysis

Subject analysis set description

Subjects who received intravenous infusion of M6620 at escalated dose of 120 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine at a dose of 500, 750, 875 or 1000 mg/m^2 on Days 1 and 8 of a 21-day cycle up to 61 weeks.

Subject analysis set title

Part A1: M6620 210 mg/m^2 and Gemcitabine

Subject analysis set type

Full analysis

Subject analysis set description

Subjects who received intravenous infusion of M6620 at escalated dose of 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine at a dose of 750, 875 or 1000 mg/m^2 on Days 1 and 8 of a 21-day cycle up to 61 weeks.

Subject analysis set title

Part B1: M6620 140 mg/m^2 and Cisplatin

Subject analysis set type

Full analysis

Subject analysis set description

Subjects who received intravenous infusion of M6620 at dose of 140mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Cisplatin at a dose of 40 or 75 mg/m^2 on Day 1 of a 21-day cycle up to 74 weeks.

Subject analysis set title

Part B1: M6620 210 mg/m^2 and Cisplatin

Subject analysis set type

Full analysis

Subject analysis set description

Subjects who received intravenous infusion of M6620 at dose of 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Cisplatin at a dose of 40, 60 or 75 mg/m^2 on Day 1 of a 21-day cycle up to 74 weeks.

Primary: Parts A1, A2, B1: Number of Subjects with Treatment-Emergent Adverse Events (TEAEs)

Top of page

End point title

Parts A1, A2, B1: Number of Subjects with Treatment-Emergent Adverse Events (TEAEs) ^[1] ^[2]

End point description

Adverse event (AE) was defined as any untoward medical occurrence in a subject, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were those events with onset dates occurring during the on-treatment period for the first time, or if the worsening of an event was during the on-treatment period. TEAEs included both serious TEAEs and non-serious TEAEs. Safety set included all subjects who received at least 1 dose of study drug.

End point type

Primary

End point timeframe

Time from first dose of study treatment up to 4.6 years

Notes
[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive summary statistics was planned for this endpoint.
[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part A1, Part A2 and Part B1 arms only. For Part B2, Part C1, C2 and C3 arms we have created separate endpoints due to change in the time frame.

End point values	Part A1: M6620 18 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 36 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 60 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 72 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 90 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 140 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 750 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part A2: M6620 90 mg/m^2 + Gemcitabine + Cisplatin	Part A2: M6620 120 mg/m^2 + Gemcitabine + Cisplatin	Part B1: M6620 140 mg/m^2	Part B1: M6620 90 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 140 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 60 mg/m^2	Part B1: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 75 mg/m^2
Number of subjects analysed	3	3	4	7	6	8	3	3	7	6	6	2	1	3	3	4	10	7	3
Units: subjects	3	3	4	6	6	8	3	3	7	6	6	2	1	3	3	3	10	7	3

No statistical analyses for this end point

Primary: Parts A1, A2, B1: Number of Subjects with Clinically Significant Changes From Baseline in Laboratory Parameters

Top of page

End point title

Parts A1, A2, B1: Number of Subjects with Clinically Significant Changes From Baseline in Laboratory Parameters ^[3] ^[4]

End point description

Laboratory investigation included hematology, biochemistry, urinalysis and coagulation. Clinical significance was determined by the investigator. The number of subjects with clinically significant changes from baseline in laboratory parameters were reported. Safety set included all subjects who received at least 1 dose of study drug.

End point type

Primary

End point timeframe

Time from first dose of study treatment up to 4.6 years

Notes
[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive summary statistics was planned for this endpoint.
[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part A1, Part A2 and Part B1 arms only. For Part B2, Part C1, C2 and C3 arms we have created separate endpoints due to change in the time frame.

End point values	Part A1: M6620 18 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 36 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 60 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 72 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 90 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 140 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 750 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part A2: M6620 90 mg/m^2 + Gemcitabine + Cisplatin	Part A2: M6620 120 mg/m^2 + Gemcitabine + Cisplatin	Part B1: M6620 140 mg/m^2	Part B1: M6620 90 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 140 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 60 mg/m^2	Part B1: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 75 mg/m^2
Number of subjects analysed	3	3	4	7	6	8	3	3	7	6	6	2	1	3	3	4	10	7	3
Units: subjects	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

No statistical analyses for this end point

Primary: Parts A1, A2, B1: Number of Subjects with Clinically Significant Changes From Baseline in Vital Signs

Top of page

End point title

Parts A1, A2, B1: Number of Subjects with Clinically Significant Changes From Baseline in Vital Signs ^[5] ^[6]

End point description

Vital signs included body temperature, systolic and diastolic blood pressure, pulse rate and respiratory rate. Clinical significance was determined by the investigator. The number of subjects with clinically significant changes fom baseline in vital signs were reported. Safety set included all subjects who received at least 1 dose of study drug.

End point type

Primary

End point timeframe

Time from first dose of study treatment up to 4.6 years

Notes
[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive summary statistics was planned for this endpoint.
[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part A1, Part A2 and Part B1 arms only. For Part B2, Part C1, C2 and C3 arms we have created separate endpoints due to change in the time frame.

End point values	Part A1: M6620 18 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 36 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 60 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 72 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 90 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 140 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 750 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part A2: M6620 90 mg/m^2 + Gemcitabine + Cisplatin	Part A2: M6620 120 mg/m^2 + Gemcitabine + Cisplatin	Part B1: M6620 140 mg/m^2	Part B1: M6620 90 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 140 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 60 mg/m^2	Part B1: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 75 mg/m^2
Number of subjects analysed	3	3	4	7	6	8	3	3	7	6	6	2	1	3	3	4	10	7	3
Units: subjects	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

No statistical analyses for this end point

Primary: Parts A1, A2, B1: Number of Subjects with Clinically Significant Changes From Baseline in 12-Lead Electrocardiograms (ECGs) Findings

Top of page

End point title

Parts A1, A2, B1: Number of Subjects with Clinically Significant Changes From Baseline in 12-Lead Electrocardiograms (ECGs) Findings ^[7] ^[8]

End point description

12-lead ECG recordings included rhythm, heart rate (as measured by RR interval), PR interval, QRS duration, and QT interval. 12-lead ECG recordings were obtained after the subjects have rested for at least 5 minutes in supine position. Clinical significance was determined by the investigator. The number of subjects with clinically significant changes from baseline in 12-lead ECG findings were reported. Safety set included all subjects who received at least 1 dose of study drug.

End point type

Primary

End point timeframe

Time from first dose of study treatment up to 4.6 years

Notes
[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive summary statistics was planned for this endpoint.
[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part A1, Part A2 and Part B1 arms only. For Part B2, Part C1, C2 and C3 arms we have created separate endpoints due to change in the time frame.

End point values	Part A1: M6620 18 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 36 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 60 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 72 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 90 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 140 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 750 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part A2: M6620 90 mg/m^2 + Gemcitabine + Cisplatin	Part A2: M6620 120 mg/m^2 + Gemcitabine + Cisplatin	Part B1: M6620 140 mg/m^2	Part B1: M6620 90 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 140 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 60 mg/m^2	Part B1: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 75 mg/m^2
Number of subjects analysed	3	3	4	7	6	8	3	3	7	6	6	2	1	3	3	4	10	7	3
Units: subjects	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

No statistical analyses for this end point

Primary: Part B2: Number of Subjects with Treatment-Emergent Adverse Events (TEAEs)

Top of page

End point title

Part B2: Number of Subjects with Treatment-Emergent Adverse Events (TEAEs) ^[9] ^[10]

End point description

Adverse event (AE) was defined as any untoward medical occurrence in a subject, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were those events with onset dates occurring during the on-treatment period for the first time, or if the worsening of an event was during the on-treatment period. TEAEs included both serious TEAEs and non-serious TEAEs. Safety Analysis Set (SAF) included all screening analysis set subjects who received at least 1 administration of study drug (irinotecan or M6620).

End point type

Primary

End point timeframe

Time from first dose of study treatment up to 1.6 years

Notes
[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive summary statistics was planned for this endpoint.
[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part B2 arms only. For Parts A1, A2, B1, C1, C2 and C3 arms we have created separate endpoints due to change in the time frame.

End point values	Part B2: M6620 60 mg/m^2 + Irinotecan 180 mg/m^2	Part B2: M6620 90 mg/m^2 + Irinotecan 180 mg/m^2
Number of subjects analysed	5	3
Units: subjects	5	3

No statistical analyses for this end point

Primary: Part B2: Number of Subjects with Clinically Significant Changes from Baseline in Laboratory Parameters

Top of page

End point title

Part B2: Number of Subjects with Clinically Significant Changes from Baseline in Laboratory Parameters ^[11] ^[12]

End point description

Laboratory investigation included hematology, biochemistry, urinalysis and coagulation. Clinical significance was determined by the investigator. The number of subjects with clinically significant changes from baseline in laboratory parameters were reported. SAF included all screening analysis set subjects who received at least 1 administration of study drug (irinotecan or M6620).

End point type

Primary

End point timeframe

Time from first dose of study treatment up to 1.6 years

Notes
[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive summary statistics was planned for this endpoint.
[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part B2 arms only. For Parts A1, A2, B1, C1, C2 and C3 arms we have created separate endpoints due to change in the time frame.

End point values	Part B2: M6620 60 mg/m^2 + Irinotecan 180 mg/m^2	Part B2: M6620 90 mg/m^2 + Irinotecan 180 mg/m^2
Number of subjects analysed	5	3
Units: subjects	0	0

No statistical analyses for this end point

Primary: Part B2: Number of Subjects with Clinically Significant Changes from Baseline in Vital Signs

Top of page

End point title

Part B2: Number of Subjects with Clinically Significant Changes from Baseline in Vital Signs ^[13] ^[14]

End point description

Vital signs included body temperature, systolic and diastolic blood pressure, pulse rate and respiratory rate. Clinical significance was determined by the investigator. The number of subjects with clinically significant changes from baseline in vital signs were reported. SAF included all screening analysis set subjects who received at least 1 administration of study drug (irinotecan or M6620).

End point type

Primary

End point timeframe

Time from first dose of study treatment up to 1.6 years

Notes
[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive summary statistics was planned for this endpoint.
[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part B2 arms only. For Parts A1, A2, B1, C1, C2 and C3 arms we have created separate endpoints due to change in the time frame.

End point values	Part B2: M6620 60 mg/m^2 + Irinotecan 180 mg/m^2	Part B2: M6620 90 mg/m^2 + Irinotecan 180 mg/m^2
Number of subjects analysed	5	3
Units: subjects	0	0

No statistical analyses for this end point

Primary: Part B2: Number of Subjects with Clinically Significant Changes from Baseline in 12-Lead Electrocardiograms (ECGs) Findings

Top of page

End point title

Part B2: Number of Subjects with Clinically Significant Changes from Baseline in 12-Lead Electrocardiograms (ECGs) Findings ^[15] ^[16]

End point description

12-lead ECG recordings included rhythm, heart rate (as measured by RR interval), PR interval, QRS duration, and QT interval. 12-lead ECG recordings were obtained after the subjects have rested for at least 5 minutes in supine position. Clinical significance was determined by the investigator. The number of subjects with clinically significant changes from baseline in 12-lead ECG findings were reported. SAF included all screening analysis set subjects who received at least 1 administration of study drug (irinotecan or M6620).

End point type

Primary

End point timeframe

Time from first dose of study treatment up to 1.6 years

Notes
[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive summary statistics was planned for this endpoint.
[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part B2 arms only. For Parts A1, A2, B1, C1, C2 and C3 arms we have created separate endpoints due to change in the time frame.

End point values	Part B2: M6620 60 mg/m^2 + Irinotecan 180 mg/m^2	Part B2: M6620 90 mg/m^2 + Irinotecan 180 mg/m^2
Number of subjects analysed	5	3
Units: subjects	0	0

No statistical analyses for this end point

Primary: Parts C1, C2, C3: Number of Subjects with Treatment-Emergent Adverse Events (TEAEs)

Top of page

End point title

Parts C1, C2, C3: Number of Subjects with Treatment-Emergent Adverse Events (TEAEs) ^[17] ^[18]

End point description

Adverse event (AE) was defined as any untoward medical occurrence in a subject, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were those events with onset dates occurring during the on-treatment period for the first time, or if the worsening of an event was during the on-treatment period. TEAEs included both serious TEAEs and non-serious TEAEs. SAF: all enrolled subjects (irrespective of biomarker status) who received at least 1 dose of study drug (M6620, gemcitabine, cisplatin, or carboplatin; actual amount > 0 mg and/or the duration of infusion > 0 minutes).

End point type

Primary

End point timeframe

Time from first dose of study treatment up to 4.3 years

Notes
[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive summary statistics was planned for this endpoint.
[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part C1, C2 and C3 arms only. For Parts A1, A2, B1 and B2 arms we have created separate endpoints due to change in the time frame.

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	38	47	2	13
Units: subjects	38	47	2	13

No statistical analyses for this end point

Primary: Parts C1, C2, C3: Number of Subjects with Clinically Significant Changes from Baseline in Laboratory Parameters

Top of page

End point title

Parts C1, C2, C3: Number of Subjects with Clinically Significant Changes from Baseline in Laboratory Parameters ^[19] ^[20]

End point description

Laboratory investigation included hematology, biochemistry, urinalysis and coagulation. Clinical significance was determined by the investigator. The number of subjects with clinically significant changes from baseline in laboratory parameters were reported. SAF: all enrolled subjects (irrespective of biomarker status) who received at least 1 dose of study drug (M6620, gemcitabine, cisplatin, or carboplatin; actual amount > 0 mg and/or the duration of infusion > 0 minutes).

End point type

Primary

End point timeframe

Time from first dose of study treatment up to 4.3 years

Notes
[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive summary statistics was planned for this endpoint.
[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Parts C1, C2 and C3 arms only. For Part A1, A2, B1 and B2 arms we have created separate endpoints due to change in the time frame.

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	38	47	2	13
Units: subjects	0	0	0	0

No statistical analyses for this end point

Primary: Parts C1, C2, C3: Number of Subjects with Clinically Significant Changes from Baseline in Vital Signs

Top of page

End point title

Parts C1, C2, C3: Number of Subjects with Clinically Significant Changes from Baseline in Vital Signs ^[21] ^[22]

End point description

Vital signs included body temperature, systolic and diastolic blood pressure, pulse rate and respiratory rate. Clinical significance was determined by the investigator. The number of subjects with clinically significant changes from baseline in vital signs were reported. SAF: all enrolled subjects (irrespective of biomarker status) who received at least 1 dose of study drug (M6620, gemcitabine, cisplatin, or carboplatin; actual amount > 0 mg and/or the duration of infusion > 0 minutes).

End point type

Primary

End point timeframe

Time from first dose of study treatment up to 4.3 years

Notes
[21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive summary statistics was planned for this endpoint.
[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Parts C1, C2 and C3 arms only. For Part A1, A2, B1 and B2 arms we have created separate endpoints due to change in the time frame.

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	38	47	2	13
Units: subjects	0	0	0	0

No statistical analyses for this end point

Primary: Parts C1, C2 and C3: Number of Subjects with Clinically Significant Changes from Baseline in 12-Lead Electrocardiograms (ECGs) Findings

Top of page

End point title

Parts C1, C2 and C3: Number of Subjects with Clinically Significant Changes from Baseline in 12-Lead Electrocardiograms (ECGs) Findings ^[23] ^[24]

End point description

12-lead ECG recordings included rhythm, heart rate (as measured by RR interval), PR interval, QRS duration, and QT interval. 12-lead ECG recordings were obtained after the subjects have rested for at least 5 minutes in supine position. Clinical significance was determined by the investigator. The number of subjects with clinically significant changes from baseline in 12-lead ECG findings were reported. SAF: all enrolled subjects (irrespective of biomarker status) who received at least 1 dose of study drug (M6620, gemcitabine, cisplatin, or carboplatin; actual amount > 0 mg and/or the duration of infusion > 0 minutes).

End point type

Primary

End point timeframe

Time from first dose of study treatment up to 4.3 years

Notes
[23] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive summary statistics was planned for this endpoint.
[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Parts C1, C2 and C3 arms only. For Part A1, A2, B1 and B2 arms we have created separate endpoints due to change in the time frame.

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	38	47	2	13
Units: subjects	0	0	0	0

No statistical analyses for this end point

Primary: Parts C1 and C3: Percentage of Subjects with Objective Response (OR)

Top of page

End point title

Parts C1 and C3: Percentage of Subjects with Objective Response (OR) ^[25] ^[26]

End point description

OR was defined as the percentage of subjects who had achieved partial response (PR) or complete response (CR) as the best overall response according to according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions. Modified Full Analysis Set (mFAS): all enrolled subjects who satisfy both of following conditions:1) Received at least 1 dose of study drug (M6620, gemcitabine, cisplatin/carboplatin with the actual amount greater than [>] 0 mg and/the duration of infusion > 0 minutes; 2) Had a Baseline scan of disease assessment (Computed tomography [CT]/Magnetic resonance imaging [MRI]) with a measurable target lesion (sum of diameters of all target lesions > 0 millimeter [mm]).

End point type

Primary

End point timeframe

Time from first dose of study treatment up to 4.3 years

Notes
[25] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive summary statistics was planned for this endpoint.
[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Parts C1 and C3 arms only. For Part A1, A2, B1, B2 and C2 arms we have created separate endpoints.

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	38	2	13
Units: percentage of subjects
number (confidence interval 90%)	10.5 (3.7 to 22.5)	0.0 (0.0 to 77.6)	0.0 (0.0 to 20.6)

No statistical analyses for this end point

Primary: Part C2: Percentage of Subjects with Objective Response (OR) in Part C2 (TNBC) Who are Basaloid Subtype and BRCA1/BRCA2 Germline wild-type

Top of page

End point title

Part C2: Percentage of Subjects with Objective Response (OR) in Part C2 (TNBC) Who are Basaloid Subtype and BRCA1/BRCA2 Germline wild-type ^[27] ^[28]

End point description

End point type

Primary

End point timeframe

Time from first dose of study treatment up to 4.3 years

Notes
[27] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive summary statistics was planned for this endpoint.
[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, the data was planned to be reported for subjects with Basaloid subtype (BRCA1/BRCA2) in Part B2 only.

End point values	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2
Number of subjects analysed	47
Units: percentage of subjects
number (confidence interval 90%)	22.6 (11.1 to 38.3)

No statistical analyses for this end point

Secondary: Parts A1 and A2: Maximum Tolerated Dose (MTD) of M6620

Top of page

End point title

Parts A1 and A2: Maximum Tolerated Dose (MTD) of M6620

End point description

Part A1: MTD of M6620 with gemcitabine was defined as the highest dose of M6620 tolerated in combination with a gemcitabine. Part A2: MTD of M6620 was defined as the highest dose of M6620 tolerated in combination with a cisplatin and gemcitabine. Dose limiting toxicity (DLT) evaluable set was defined as all subjects enrolled in Part A or Part B1 who either had a DLT before Day 21 in Cycle 1; or received all doses of gemcitabine and/or cisplatin, as applicable, and all doses of M6620 during Cycle.

End point type

Secondary

End point timeframe

Up to Cycle 1 Day 21 (each cycle is 21 days)

End point values	Part A1: All Subjects	Part A2: All Subjects
Number of subjects analysed	50	8
Units: mg/m^2
number (not applicable)	210	90

No statistical analyses for this end point

Secondary: Part A1: Maximum Observed Plasma Concentration (Cmax) of M6620

Top of page

End point title

Part A1: Maximum Observed Plasma Concentration (Cmax) of M6620 ^[29]

End point description

Cmax was obtained directly from the concentration versus time curve. Full Analysis Set (FAS) included all subjects who had baseline scan and received at least 1 dose of study drug and had at least once post-baseline disease assessment (including staging CT scan or nonstaging CT scan indicating disease progression, end of treatment due to progression disease [PD] or death).

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3 and 7 hours after end of infusion (EOI) on Cycle 1 Day 2 (each cycle is of 21 days)

Notes
[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part A1 arms only. For Parts A2, B1, B2, C1, C2 and C3 arms we have created separate endpoints.

End point values	Part A1: M6620 90 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 120 mg/m^2 and Gemcitabine	Part A1: M6620 210 mg/m^2 and Gemcitabine
Number of subjects analysed	6	2	16
Units: nanogram per milliliter (ng/mL)
geometric mean (geometric coefficient of variation)	571 ( 34 )	486 ( 28 )	899 ( 41 )

No statistical analyses for this end point

Secondary: Part A1: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of M6620

Top of page

End point title

Part A1: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of M6620 ^[30]

End point description

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ lambda z, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLOQ) and lambda z is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase. FAS included all subjecst who had baseline scan, received at least 1 dose of study drug and had at least once post-baseline disease assessment (including staging CT scan or nonstaging CT scan indicating disease progression, end of treatment due to progression disease [PD] or death).

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3 and 7 hours after end of infusion (EOI) on Cycle 1 Day 2 (each cycle is of 21 days)

Notes
[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part A1 arms only. For Parts A2, B1, B2, C1, C2 and C3 arms we have created separate endpoints.

End point values	Part A1: M6620 90 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 120 mg/m^2 and Gemcitabine	Part A1: M6620 210 mg/m^2 and Gemcitabine
Number of subjects analysed	6	2	16
Units: nanogramhour per milliliter (nghr/mL)
geometric mean (geometric coefficient of variation)	3100 ( 39 )	4160 ( 3.5 )	6690 ( 31 )

No statistical analyses for this end point

Secondary: Part A1: Apparent Volume of Distribution at Steady-state (Vss) of M6620

Top of page

End point title

Part A1: Apparent Volume of Distribution at Steady-state (Vss) of M6620 ^[31]

End point description

Vss was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) was the apparent volume of distribution at steady-state. FAS included all subjects who had baseline scan, received at least 1 dose of study drug and had at least once post-baseline disease assessment (including staging CT scan or nonstaging CT scan indicating disease progression, end of treatment due to progression disease [PD] or death).

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3 and 7 hours after end of infusion (EOI) on Cycle 1 Day 2 (each cycle is of 21 days)

Notes
[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part A1 arms only. For Parts A2, B1, B2, C1, C2 and C3 arms we have created separate endpoints.

End point values	Part A1: M6620 90 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 120 mg/m^2 and Gemcitabine	Part A1: M6620 210 mg/m^2 and Gemcitabine
Number of subjects analysed	6	2	16
Units: liters
geometric mean (geometric coefficient of variation)	983 ( 35 )	1240 ( 14 )	1250 ( 22 )

No statistical analyses for this end point

Secondary: Part A1: Apparent Total Body Clearance (CL) of M6620

Top of page

End point title

Part A1: Apparent Total Body Clearance (CL) of M6620 ^[32]

End point description

CL was a measure of the rate at which M6620 was metabolized or eliminated by normal biological processes. Clearance obtained after oral dose was influenced by the fraction of the dose absorbed. FAS included all subjects who had baseline scan, received at least 1 dose of study drug and had at least once post-baseline disease assessment (including staging CT scan or nonstaging CT scan indicating disease progression, end of treatment due to PD or death).

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3 and 7 hours after end of infusion (EOI) on Cycle 1 Day 2 (each cycle is of 21 days)

Notes
[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part A1 arms only. For Parts A2, B1, B2, C1, C2 and C3 arms we have created separate endpoints.

End point values	Part A1: M6620 90 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 120 mg/m^2 and Gemcitabine	Part A1: M6620 210 mg/m^2 and Gemcitabine
Number of subjects analysed	6	2	16
Units: liter per hour
geometric mean (geometric coefficient of variation)	64.2 ( 45 )	55.5 ( 1 )	62.3 ( 31 )

No statistical analyses for this end point

Secondary: Part A1: Apparent Terminal Half-Life (t1/2) of M6620

Top of page

End point title

Part A1: Apparent Terminal Half-Life (t1/2) of M6620 ^[33]

End point description

Apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50 percent in the final stage of its elimination. FAS included all subjects who had baseline scan, received at least 1 dose of study drug and had at least once post-baseline disease assessment (including staging CT scan or nonstaging CT scan indicating disease progression, end of treatment due to PD or death).

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3 and 7 hours after end of infusion (EOI) on Cycle 1 Day 2 (each cycle is of 21 days)

Notes
[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part A1 arms only. For Parts A2, B1, B2, C1, C2 and C3 arms we have created separate endpoints.

End point values	Part A1: M6620 90 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 120 mg/m^2 and Gemcitabine	Part A1: M6620 210 mg/m^2 and Gemcitabine
Number of subjects analysed	6	2	16
Units: hours
geometric mean (geometric coefficient of variation)	14.2 ( 27 )	17.6 ( 14 )	17.3 ( 24 )

No statistical analyses for this end point

Secondary: Parts A1, A2 and B1: Percentage of Subjects with Objective Tumor Response (OR) as Evaluated by Response Criteria Evaluation in Solid Tumors (RECIST) 1.1

Top of page

End point title

Parts A1, A2 and B1: Percentage of Subjects with Objective Tumor Response (OR) as Evaluated by Response Criteria Evaluation in Solid Tumors (RECIST) 1.1 ^[34]

End point description

Objective tumor response was defined as having a complete response (CR) or a partial response (PR). Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. FAS included all subjecst who had baseline scan, received at least 1 dose of study drug and had at least once post-baseline disease assessment (including staging CT scan or nonstaging CT scan indicating disease progression, end of treatment due to PD or death). Here, "number of subjects analyzed" signifies those subjects who were evaluable for this endpoint. Here, '99999' signifies that data is not available as none of the subjects showed CR or PR at specified time point.

End point type

Secondary

End point timeframe

Time from first dose of study treatment up to 4.6 years

Notes
[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part A1, Part A2 and Part B1 arms only. For Part B2, Part C1, C2 and C3 arms we have created separate endpoints due to change in the time frame.

Part A1: M6620 18 mg/m^2 + Gemcitabine 875 mg/m^2

Part A1: M6620 36 mg/m^2 + Gemcitabine 875 mg/m^2

Part A1: M6620 60 mg/m^2 + Gemcitabine 875 mg/m^2

Part A1: M6620 72 mg/m^2 + Gemcitabine 875 mg/m^2

Part A1: M6620 90 mg/m^2 + Gemcitabine 500 mg/m^2

Part A1: M6620 140 mg/m^2 + Gemcitabine 500 mg/m^2

Part A1: M6620 210 mg/m^2 + Gemcitabine 500 mg/m^2

Part A1: M6620 210 mg/m^2 + Gemcitabine 750 mg/m^2

Part A1: M6620 210 mg/m^2 + Gemcitabine 875 mg/m^2

Part A1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2

Part A2: M6620 90 mg/m^2 + Gemcitabine + Cisplatin

Part A2: M6620 120 mg/m^2 + Gemcitabine + Cisplatin

Part B1: M6620 90 mg/m^2 + Cisplatin 40 mg/m^2

Part B1: M6620 140 mg/m^2 + Cisplatin 40 mg/m^2

Part B1: M6620 210 mg/m^2 + Cisplatin 40 mg/m^2

Part B1: M6620 210 mg/m^2 + Cisplatin 60 mg/m^2

Part B1: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2

Part B1: M6620 210 mg/m^2 + Cisplatin 75 mg/m^2

Number of subjects analysed

Units: percentage of subjects

number (confidence interval 90%)

99999 (99999 to 99999)

33.3 (1.7 to 86.5)

99999 (99999 to 99999)

28.6 (5.3 to 65.9)

99999 (99999 to 99999)

33.3 (1.7 to 86.5)

99999 (99999 to 99999)

16.7 (0.9 to 58.2)

99999 (99999 to 99999)

25.0 (1.3 to 75.1)

99999 (99999 to 99999)

75.0 (24.9 to 98.7)

99999 (99999 to 99999)

No statistical analyses for this end point

Secondary: Part B1: Maximum Tolerated Dose (MTD) of M6620

Top of page

End point title

Part B1: Maximum Tolerated Dose (MTD) of M6620

End point description

M6620 MTD was defined as the highest dose of M6620 tolerated in combination with a cisplatin. DLT evaluable set was defined as all subjects enrolled in Part A or Part B1 who either had a DLT before Day 21 in Cycle 1; or received all doses of gemcitabine and/or cisplatin, as applicable, and all doses of M6620 during Cycle.

End point type

Secondary

End point timeframe

Up to Cycle 1 Day 21 (each cycle is 21 days)

End point values	Parts B1: All Subjects
Number of subjects analysed	31
Units: mg/m^2
number (not applicable)	140

No statistical analyses for this end point

Secondary: Part B2: Maximum Tolerated Dose (MTD) of M6620

Top of page

End point title

Part B2: Maximum Tolerated Dose (MTD) of M6620

End point description

The MTD for M6620 in combination with irinotecan was defined as the highest dose for a given schedule at which there were no more than 1 of 6 subjects with DLT. DLT Evaluable Set: all SAF subjects who either experienced a DLT before the end of Cycle 1 and received any amount of M6620 or received at least 80% of the cumulative planned dose of irinotecan and at least 80% of the cumulative planned dose of M6620 during Cycle 1 and completed Cycle 1, i.e., had a study visit on Day 28 or later

End point type

Secondary

End point timeframe

Up to Cycle 1 Day 28 (each cycle is of 28 days)

End point values	Part B2: All Subjects
Number of subjects analysed	0 ^[35]
Units: mg/m^2
number (not applicable)

Notes
[35] - MTD was not determined as Part B2 was discontinued after observing toxicities at first dose level.

No statistical analyses for this end point

Secondary: Part B1: Maximum Observed Plasma Concentration (Cmax) of M6620

Top of page

End point title

Part B1: Maximum Observed Plasma Concentration (Cmax) of M6620 ^[36]

End point description

Cmax was obtained directly from the concentration versus time curve. FAS included all subjects who had baseline scan, received at least 1 dose of study drug and had at least once post-baseline disease assessment (including staging CT scan or nonstaging CT scan indicating disease progression, end of treatment due to PD or death).

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3 and 7 hours after EOI on Cycle 1 Day 2 (each cycle is 21 days)

Notes
[36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part B1 arms only. For Parts A1, A2, B2, C1, C2 and C3 arms we have created separate endpoints.

End point values	Part B1: M6620 90 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 140 mg/m^2 and Cisplatin	Part B1: M6620 210 mg/m^2 and Cisplatin
Number of subjects analysed	2	8	17
Units: nanogram per milliliter (ng/mL)
geometric mean (geometric coefficient of variation)	458 ( 13 )	854 ( 63 )	1230 ( 43 )

No statistical analyses for this end point

Secondary: Part B1: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of M6620

Top of page

End point title

Part B1: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of M6620 ^[37]

End point description

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ lambda z, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLOQ) and lambda z is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase. FAS included all subjects who had baseline scan, received at least 1 dose of study drug and had at least once post-baseline disease assessment (including staging CT scan or nonstaging CT scan indicating disease progression, end of treatment due to PD or death).

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3 and 7 hours after EOI on Cycle 1 Day 2 (each cycle is 21 days)

Notes
[37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part B1 arms only. For Parts A1, A2, B2, C1, C2 and C3 arms we have created separate endpoint.

End point values	Part B1: M6620 90 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 140 mg/m^2 and Cisplatin	Part B1: M6620 210 mg/m^2 and Cisplatin
Number of subjects analysed	2	8	17
Units: nanogramhour per milliliter (nghr/mL)
geometric mean (geometric coefficient of variation)	2820 ( 15 )	4870 ( 28 )	6740 ( 32 )

No statistical analyses for this end point

Secondary: Part B1: Apparent Volume of Distribution at Steady-state (Vss) of M6620

Top of page

End point title

Part B1: Apparent Volume of Distribution at Steady-state (Vss) of M6620 ^[38]

End point description

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3 and 7 hours after EOI on Cycle 1 Day 2 (each cycle is 21 days)

Notes
[38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part B1 arms only. For Parts A1, A2, B2, C1, C2 and C3 arms we have created separate endpoints.

End point values	Part B1: M6620 90 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 140 mg/m^2 and Cisplatin	Part B1: M6620 210 mg/m^2 and Cisplatin
Number of subjects analysed	2	8	17
Units: liters
geometric mean (geometric coefficient of variation)	1260 ( 38 )	1060 ( 36 )	1270 ( 28 )

No statistical analyses for this end point

Secondary: Part B1: Apparent Total Body Clearance (CL) of M6620

Top of page

End point title

Part B1: Apparent Total Body Clearance (CL) of M6620 ^[39]

End point description

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3 and 7 hours after EOI on Cycle 1 Day 2 (each cycle is 21 days)

Notes
[39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part B1 arms only. For Parts A1, A2, B2, C1, C2 and C3 arms we have created separate endpoints.

End point values	Part B1: M6620 90 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 140 mg/m^2 and Cisplatin	Part B1: M6620 210 mg/m^2 and Cisplatin
Number of subjects analysed	2	8	17
Units: liters
geometric mean (geometric coefficient of variation)	61.1 ( 20 )	54.7 ( 31 )	62.6 ( 32 )

No statistical analyses for this end point

Secondary: Part B1: Apparent Terminal Half-Life (t1/2) of M6620

Top of page

End point title

Part B1: Apparent Terminal Half-Life (t1/2) of M6620 ^[40]

End point description

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3 and 7 hours after EOI on Cycle 1 Day 2 (each cycle is 21 days)

Notes
[40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part B1 arms only. For Parts A1, A2, B2, C1, C2 and C3 arms we have created separate endpoints.

End point values	Part B1: M6620 90 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 140 mg/m^2 and Cisplatin	Part B1: M6620 210 mg/m^2 and Cisplatin
Number of subjects analysed	2	8	17
Units: hours
geometric mean (geometric coefficient of variation)	17.0 ( 26 )	17.5 ( 34 )	17.3 ( 17 )

No statistical analyses for this end point

Secondary: Part B2: Maximum Observed Plasma Concentration (Cmax) of M6620

Top of page

End point title

Part B2: Maximum Observed Plasma Concentration (Cmax) of M6620 ^[41]

End point description

Cmax was obtained directly from the concentration versus time curve. Pharmacokinetic Analysis Set (PAS) included all SAF subjects who received at least 1 administration of study drug (irinotecan or M6620) and provided at least 1 measurable postdose concentration of M6620 or irinotecan or its metabolites.

End point type

Secondary

End point timeframe

Cycle 1 Days 1 through 3: pre-infusion, and 1, 2, 3, 7, 23 and 47 hours after EOI; Cycle 1 Day 15 and Cycle 2 Day 1 at pre-infusion, and EOI to 2 hours after EOI (each cycle is of 28 days)

Notes
[41] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part B2 arms only. For Parts A1, A2, B1, C1, C2 and C3 arms we have created separate endpoints.

End point values	Part B2: M6620 60 mg/m^2 + Irinotecan 180 mg/m^2	Part B2: M6620 90 mg/m^2 + Irinotecan 180 mg/m^2
Number of subjects analysed	0 ^[42]	0 ^[43]
Units: ng/mL
geometric mean (geometric coefficient of variation)	( )	( )

Notes
[42] - As per revised planned analysis, pharmacokinetic parameters for Part B2 was not assessed.
[43] - As per revised planned analysis, pharmacokinetic parameters for Part B2 was not assessed.

No statistical analyses for this end point

Secondary: Part B2: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of M6620

Top of page

End point title

Part B2: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of M6620 ^[44]

End point description

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ lambda z, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLOQ) and lambda z is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase. PAS included all SAF subjects who received at least 1 administration of study drug (irinotecan or M6620) and provided at least 1 measurable postdose concentration of M6620 or irinotecan or its metabolites.

End point type

Secondary

End point timeframe

Cycle 1 Days 1 through 3: pre-infusion, and 1, 2, 3, 7, 23 and 47 hours after EOI; Cycle 1 Day 15 and Cycle 2 Day 1 at pre-infusion, and EOI to 2 hours after EOI (each cycle is of 28 days)

Notes
[44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part B2 arms only. For Parts A1, A2, B1, C1, C2 and C3 arms we have created separate endpoints.

End point values	Part B2: M6620 60 mg/m^2 + Irinotecan 180 mg/m^2	Part B2: M6620 90 mg/m^2 + Irinotecan 180 mg/m^2
Number of subjects analysed	0 ^[45]	0 ^[46]
Units: ng*hr/mL
geometric mean (geometric coefficient of variation)	( )	( )

Notes
[45] - As per revised planned analysis, pharmacokinetic parameters for Part B2 was not assessed.
[46] - As per revised planned analysis, pharmacokinetic parameters for Part B2 was not assessed.

No statistical analyses for this end point

Secondary: Part B2: Volume of Distribution at Steady-state (Vss) of M6620

Top of page

End point title

Part B2: Volume of Distribution at Steady-state (Vss) of M6620 ^[47]

End point description

Vss was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) was the apparent volume of distribution at steady-state. PAS included all SAF subjects who received at least 1 administration of study drug (irinotecan or M6620) and provided at least 1 measurable postdose concentration of M6620 or irinotecan or its metabolites

End point type

Secondary

End point timeframe

Cycle 1 Days 1 through 3: pre-infusion, and 1, 2, 3, 7, 23 and 47 hours after EOI; Cycle 1 Day 15 and Cycle 2 Day 1 at pre-infusion, and EOI to 2 hours after EOI (each cycle is of 28 days)

Notes
[47] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part B2 arms only. For Parts A1, A2, B1, C1, C2 and C3 arms we have created separate endpoints.

End point values	Part B2: M6620 60 mg/m^2 + Irinotecan 180 mg/m^2	Part B2: M6620 90 mg/m^2 + Irinotecan 180 mg/m^2
Number of subjects analysed	0 ^[48]	0 ^[49]
Units: liters
geometric mean (geometric coefficient of variation)	( )	( )

Notes
[48] - As per revised planned analysis, pharmacokinetic parameters for Part B2 was not assessed.
[49] - As per revised planned analysis, pharmacokinetic parameters for Part B2 was not assessed.

No statistical analyses for this end point

Secondary: Part B2: Apparent Total Body Clearance (CL) of M6620

Top of page

End point title

Part B2: Apparent Total Body Clearance (CL) of M6620 ^[50]

End point description

CL was a measure of the rate at which M6620 was metabolized or eliminated by normal biological processes. Clearance obtained after oral dose was influenced by the fraction of the dose absorbed. PAS included all SAF subjects who received at least 1 administration of study drug (irinotecan or M6620) and provided at least 1 measurable postdose concentration of M6620 or irinotecan or its metabolites.

End point type

Secondary

End point timeframe

Cycle 1 Days 1 through 3: pre-infusion, and 1, 2, 3, 7, 23 and 47 hours after EOI; Cycle 1 Day 15 and Cycle 2 Day 1 at pre-infusion, and EOI to 2 hours after EOI (each cycle is of 28 days)

Notes
[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part B2 arms only. For Parts A1, A2, B1, C1, C2 and C3 arms we have created separate endpoints.

End point values	Part B2: M6620 60 mg/m^2 + Irinotecan 180 mg/m^2	Part B2: M6620 90 mg/m^2 + Irinotecan 180 mg/m^2
Number of subjects analysed	0 ^[51]	0 ^[52]
Units: liter per hour
geometric mean (geometric coefficient of variation)	( )	( )

Notes
[51] - As per revised planned analysis, pharmacokinetic parameters for Part B2 was not assessed.
[52] - As per revised planned analysis, pharmacokinetic parameters for Part B2 was not assessed.

No statistical analyses for this end point

Secondary: Part B2: Apparent Terminal Half-Life (t1/2) of M6620

Top of page

End point title

Part B2: Apparent Terminal Half-Life (t1/2) of M6620 ^[53]

End point description

Apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50 percent in the final stage of its elimination. PAS included all SAF subjects who received at least 1 administration of study drug (irinotecan or M6620) and provided at least 1 measurable postdose concentration of M6620 or irinotecan or its metabolites.

End point type

Secondary

End point timeframe

Cycle 1 Days 1 through 3: pre-infusion, and 1, 2, 3, 7, 23 and 47 hours after EOI; Cycle 1 Day 15 and Cycle 2 Day 1 at pre-infusion, and EOI to 2 hours after EOI (each cycle is of 28 days)

Notes
[53] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part B2 arms only. For Parts A1, A2, B1, C1, C2 and C3 arms we have created separate endpoints.

End point values	Part B2: M6620 60 mg/m^2 + Irinotecan 180 mg/m^2	Part B2: M6620 90 mg/m^2 + Irinotecan 180 mg/m^2
Number of subjects analysed	0 ^[54]	0 ^[55]
Units: hours
geometric mean (geometric coefficient of variation)	( )	( )

Notes
[54] - As per revised planned analysis, pharmacokinetic parameters for Part B2 was not assessed.
[55] - As per revised planned analysis, pharmacokinetic parameters for Part B2 was not assessed.

No statistical analyses for this end point

Secondary: Part B2: Percentage of Subjects with Objective Tumor Response (OR) as Evaluated by Response Criteria Evaluation in Solid Tumors (RECIST) 1.1

Top of page

End point title

Part B2: Percentage of Subjects with Objective Tumor Response (OR) as Evaluated by Response Criteria Evaluation in Solid Tumors (RECIST) 1.1 ^[56]

End point description

End point type

Secondary

End point timeframe

Time from first dose of study treatment up to 1.6 years

Notes
[56] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Part B2 arms only. For Parts A1, A2, B1, C1, C2 and C3 arms we have created separate endpoints.

End point values	Part B2: M6620 60 mg/m^2 + Irinotecan 180 mg/m^2	Part B2: M6620 90 mg/m^2 + Irinotecan 180 mg/m^2
Number of subjects analysed	0 ^[57]	0 ^[58]
Units: percentage of subjects
number (confidence interval 90%)	( to )	( to )

Notes
[57] - OR was not calculated as Part B2 was discontinued after observing toxicities at first dose level.
[58] - OR was not calculated as Part B2 was discontinued after observing toxicities at first dose level.

No statistical analyses for this end point

Secondary: Part C2: Percentage of Subjects with Objective Response (OR)

Top of page

End point title

Part C2: Percentage of Subjects with Objective Response (OR) ^[59]

End point description

OR was defined as the percentage of subjects who had achieved partial response (PR) or complete response (CR) as the best overall response according to according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions. mFAS: all enrolled subjects who satisfy both of following conditions:1) Received at least 1 dose of study drug (M6620, gemcitabine, cisplatin/carboplatin with the actual amount greater than [>] 0 mg and/the duration of infusion > 0 minutes; 2) Had a Baseline scan of disease assessment (Computed tomography [CT]/Magnetic resonance imaging [MRI]) with a measurable target lesion (sum of diameters of all target lesions > 0 millimeter [mm]).

End point type

Secondary

End point timeframe

Time from first dose of study treatment up to 4.3 years

Notes
[59] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, the data was planned to be reported for Part C2 arm only.

End point values	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2
Number of subjects analysed	47
Units: percentage of subjects
number (confidence interval 90%)	23.4 (13.7 to 35.8)

No statistical analyses for this end point

Secondary: Parts C1, C2, C3: Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

Top of page

End point title

Parts C1, C2, C3: Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) ^[60]

End point description

PFS according to RECIST v1.1 was defined as the time from the date of the first dose of a study drug to the date of the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. PD was defined as at least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. mFAS: all enrolled subjects who satisfy both of following conditions:1) Received at least 1 dose of study drug (M6620, gemcitabine, cisplatin/carboplatin with the actual amount greater than [>] 0 mg and/the duration of infusion > 0 minutes; 2) Had a Baseline scan of disease assessment (Computed tomography [CT]/Magnetic resonance imaging [MRI]) with a measurable target lesion (sum of diameters of all target lesions > 0 millimeter [mm]).

End point type

Secondary

End point timeframe

Time from first dose of study treatment to 4.3 years

Notes
[60] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, the data was planned to be reported for Parts C1, C2 and C3 arms only .

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	38	47	2	13
Units: months
median (confidence interval 90%)	4.0 (3.2 to 5.0)	4.0 (2.8 to 6.0)	3.3 (1.2 to 5.3)	1.9 (1.4 to 2.1)

No statistical analyses for this end point

Secondary: Parts C1, C2, C3: Duration of Response (DoR)

Top of page

End point title

Parts C1, C2, C3: Duration of Response (DoR) ^[61]

End point description

DoR was calculated only for those subjects who achieved a CR or PR and was measured from the time the response criteria were first met for CR/PR (whichever was recorded first) until the first date that recurrent or PD was objectively documented. FAS: all enrolled subjects who satisfy both of following conditions: 1) Received at least 1 dose of study drug (M6620, gemcitabine, cisplatin/carboplatin with the actual amount greater than [>] 0 mg and/the duration of infusion > 0 minutes; 2) Had a Baseline scan of disease assessment (Computed tomography [CT]/Magnetic resonance imaging [MRI]) with a measurable target lesion (sum of diameters of all target lesions > 0 millimeter [mm]). As there were no responders (CR or PR) in Part C3 (mFAS), the analysis of DoR is presented for Parts C1 and C2 only. Here, "number of subjects snalyzed" signifies those subjects who were evaluable for this endpoint .

End point type

Secondary

End point timeframe

Time from first dose of study treatment to 4.3 years

Notes
[61] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, the data was planned to be reported for Parts C1, C2 and C3 arms only .

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	4	11	0 ^[62]	0 ^[63]
Units: months
median (full range (min-max))	6.0 (3.6 to 13.2)	6.0 (3.0 to 28.6)	( to )	( to )

Notes
[62] - None of subjects showed complete response or partial response.
[63] - None of subjects showed complete response or partial response.

No statistical analyses for this end point

Secondary: Parts C1, C2, C3: Overall Survival (OS)

Top of page

End point title

Parts C1, C2, C3: Overall Survival (OS) ^[64]

End point description

OS time was defined as the time from the date of the first dose of a study drug to death due to any cause. mFAS: all enrolled subjects who satisfy both of following conditions:1) Received at least 1 dose of study drug (M6620, gemcitabine, cisplatin/carboplatin with the actual amount greater than [>] 0 mg and/the duration of infusion > 0 minutes; 2) Had a Baseline scan of disease assessment (Computed tomography [CT]/Magnetic resonance imaging [MRI]) with a measurable target lesion (sum of diameters of all target lesions > 0 millimeter [mm]).

End point type

Secondary

End point timeframe

Time from first dose of study treatment to 4.3 years

Notes
[64] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, the data was planned to be reported for Parts C1, C2 and C3 arms only .

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	38	47	2	13
Units: months
median (full range (min-max))	7.4 (0.8 to 28.2)	12.4 (1.4 to 31.6)	7.0 (6.3 to 7.0)	5.5 (0.8 to 16.4)

No statistical analyses for this end point

Secondary: Parts C1, C2, C3: Percentage of Subjects with Clinical benefit (Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) of 6 months or greater)

Top of page

End point title

Parts C1, C2, C3: Percentage of Subjects with Clinical benefit (Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) of 6 months or greater) ^[65]

End point description

Clinical benefit rate was defined as the proportion of subjects who achieved a BOR of CR, PR or SD greater than or equal to [>=] 6 months. mFAS: all enrolled subjects who satisfy both of following conditions:1) Received at least 1 dose of study drug (M6620, gemcitabine, cisplatin/carboplatin with the actual amount greater than [>] 0 mg and/the duration of infusion > 0 minutes; 2) Had a Baseline scan of disease assessment (Computed tomography [CT]/Magnetic resonance imaging [MRI]) with a measurable target lesion (sum of diameters of all target lesions > 0 millimeter [mm]).

End point type

Secondary

End point timeframe

Time from first dose of study treatment to 4.3 years

Notes
[65] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, the data was planned to be reported for Parts C1, C2 and C3 arms only .

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	38	47	2	13
Units: percentage of subjects
number (confidence interval 90%)	15.8 (7.1 to 28.8)	27.7 (17.2 to 40.3)	0 (0.0 to 77.6)	0 (0.0 to 20.6)

No statistical analyses for this end point

Secondary: Parts C1, C2 and C3: Maximum Observed Plasma Concentration (Cmax) of M6620

Top of page

End point title

Parts C1, C2 and C3: Maximum Observed Plasma Concentration (Cmax) of M6620 ^[66]

End point description

Cmax was obtained directly from the concentration versus time curve. PAS included all subjects who received at least 1 dose of M6620 (with the actual amount > 0 mg and/or the duration of infusion > 0 minutes), and provided at least 1 measurable post-dose concentration. Here, "number of subjects analyzed" signifies those subjects who were evaluable for this endpoint at given time points. Here, "99999" signifies that geometric coefficient of variation was not calculated.

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3 and 7 hours after end of infusion (EOI) on Cycle 1 Day 2 (each cycle is of 21 days)

Notes
[66] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Parts C1, C2 and C3 arms only. For Part A1, A2, B1 and B2 arms we have created separate endpoints.

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	35	37	2	12
Units: nanogram per milliliter (ng/mL)
geometric mean (geometric coefficient of variation)	882 ( 55.2 )	555 ( 42.9 )	683 ( 99999 )	528 ( 46.9 )

No statistical analyses for this end point

Secondary: Parts C1, C2 and C3: Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Sampling Time (tlast) of M6620

Top of page

End point title

Parts C1, C2 and C3: Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Sampling Time (tlast) of M6620 ^[67]

End point description

Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. PAS included all subjects who received at least 1 dose of M6620 (with the actual amount > 0 mg and/or the duration of infusion > 0 minutes), and provided at least 1 measurable post-dose concentration. Here, "number of subjects analyzed" signifies those subjects who were evaluable for this endpoint at given time points. Here, "3.3333" signifies that median was not calculated.

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3 and 7 hours after end of infusion (EOI) on Cycle 1 Day 2 (each cycle is of 21 days)

Notes
[67] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Parts C1, C2 and C3 arms only. For Part A1, A2, B1 and B2 arms we have created separate endpoints.

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	35	37	2	12
Units: hours
median (full range (min-max))	4.00 (3.00 to 8.00)	4.00 (3.67 to 8.07)	3.3333 (2.00 to 4.00)	4.03 (3.68 to 8.00)

No statistical analyses for this end point

Secondary: Parts C1, C2 and C3: Time to Reach Maximum Plasma Concentration (Tmax) of M6620

Top of page

End point title

Parts C1, C2 and C3: Time to Reach Maximum Plasma Concentration (Tmax) of M6620 ^[68]

End point description

Tmax is time to reach maximum observed plasma concentration obtained directly from the concentration versus time curve. PAS included all subjects who received at least 1 dose of M6620 (with the actual amount > 0 mg and/or the duration of infusion > 0 minutes), and provided at least 1 measurable post-dose concentration. Here, "number of subjects analyzed" signifies those subjects who were evaluable for this endpoint at given time points.

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3 and 7 hours after end of infusion (EOI) on Cycle 1 Day 2 (each cycle is of 21 days)

Notes
[68] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Parts C1, C2 and C3 arms only. For Part A1, A2, B1 and B2 arms we have created separate endpoints.

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	35	37	2	12
Units: hours
median (full range (min-max))	0.917 (0.483 to 2.28)	0.917 (0.500 to 2.00)	0.742 (0.533 to 0.950)	0.967 (0.467 to 1.23)

No statistical analyses for this end point

Secondary: Parts C1, C2 and C3: Area Under the Plasma Concentration-Time Curve From Time Zero to 4 hours [hr] (AUC0-4hr) of of M6620

Top of page

End point title

Parts C1, C2 and C3: Area Under the Plasma Concentration-Time Curve From Time Zero to 4 hours [hr] (AUC0-4hr) of of M6620 ^[69]

End point description

Area under the plasma concentration-time curve from time 0 to 4 hours post-dose (AUC0-4) was calculated using the linear trapezoidal rule. PAS included all subjects who received at least 1 dose of M6620 (with the actual amount > 0 mg and/or the duration of infusion > 0 minutes), and provided at least 1 measurable post-dose concentration. Here, "number of subjects analyzed" signifies those subjects who were evaluable for this endpoint at given time points. Here, "99999" signifies that geometric coefficient of variation was not calculated.

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3 and 4 hours after end of infusion (EOI) on Cycle 1 Day 2 (each cycle is of 21 days)

Notes
[69] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Parts C1, C2 and C3 arms only. For Part A1, A2, B1 and B2 arms we have created separate endpoints.

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	35	34	2	12
Units: ng*hr/mL
geometric mean (geometric coefficient of variation)	1600 ( 35.8 )	1110 ( 26.4 )	1030 ( 99999 )	693 ( 32.9 )

No statistical analyses for this end point

Secondary: Parts C1, C2 and C3: Area Under the Plasma Concentration-Time Curve From Time Zero to 8 hours [hr] (AUC0-8 hr) of of M6620

Top of page

End point title

Parts C1, C2 and C3: Area Under the Plasma Concentration-Time Curve From Time Zero to 8 hours [hr] (AUC0-8 hr) of of M6620 ^[70]

End point description

Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) was calculated using the linear trapezoidal rule. PAS included all subjects who received at least 1 dose of M6620 (with the actual amount > 0 mg and/or the duration of infusion > 0 minutes), and provided at least 1 measurable post-dose concentration. Here, "number of subjects analyzed" signifies those subjects who were evaluable for this endpoint at given time points. Here, "99999" signifies that geometric coefficient of variation was not calculated.

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3 and 7 hours after end of infusion (EOI) on Cycle 1 Day 2 (each cycle is of 21 days)

Notes
[70] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Parts C1, C2 and C3 arms only. For Part A1, A2, B1 and B2 arms we have created separate endpoints.

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	3	2	0 ^[71]	2
Units: ng*hr/mL
geometric mean (geometric coefficient of variation)	2000 ( 10.9 )	1800 ( 99999 )	( )	970 ( 99999 )

Notes
[71] - None of subjects were evaluable at the given timepoints.

No statistical analyses for this end point

Secondary: Parts C1, C2 and C3: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Sampling Time (AUC0-t) of of M6620

Top of page

End point title

Parts C1, C2 and C3: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Sampling Time (AUC0-t) of of M6620 ^[72]

End point description

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3, and 7 hours after end of infusion (EOI) on Cycle 1 Day 2 (each cycle is of 21 days)

Notes
[72] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Parts C1, C2 and C3 arms only. For Part A1, A2, B1 and B2 arms we have created separate endpoints.

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	35	37	2	12
Units: ng*hr/mL
geometric mean (geometric coefficient of variation)	1660 ( 35.8 )	1110 ( 28.8 )	910 ( 99999 )	730 ( 36.0 )

No statistical analyses for this end point

Secondary: Parts C1, C2 and C3: Dose Normalized Maximum Concentration (Cmax/Dose_mg ) of M6620

Top of page

End point title

Parts C1, C2 and C3: Dose Normalized Maximum Concentration (Cmax/Dose_mg ) of M6620 ^[73]

End point description

Dose normalized was calculated as Cmax obtained directly from the concentration versus time curve divided by dose. PAS included all subjects who received at least 1 dose of M6620 (with the actual amount > 0 mg and/or the duration of infusion > 0 minutes), and provided at least 1 measurable post-dose concentration. Here, "number of subjects analyzed" signifies those subjects who were evaluable for this endpoint at given time points. Here, "99999" signifies that geometric coefficient of variation was not calculated.

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3, and 7 hours after end of infusion (EOI) on Cycle 1 Day 2 (each cycle is of 21 days)

Notes
[73] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Parts C1, C2 and C3 arms only. For Part A1, A2, B1 and B2 arms we have created separate endpoints.

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	35	37	2	12
Units: ng/mL/mg
geometric mean (geometric coefficient of variation)	2.37 ( 52.4 )	2.18 ( 44.6 )	2.72 ( 99999 )	3.24 ( 54.4 )

No statistical analyses for this end point

Secondary: Parts C1, C2 and C3: Dose Normalized Maximum Concentration (Cmax/Dose_mg/m^2) of M6620

Top of page

End point title

Parts C1, C2 and C3: Dose Normalized Maximum Concentration (Cmax/Dose_mg/m^2) of M6620 ^[74]

End point description

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3, and 7 hours after end of infusion (EOI) on Cycle 1 Day 2 (each cycle is of 21 days)

Notes
[74] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Parts C1, C2 and C3 arms only. For Part A1, A2, B1 and B2 arms we have created separate endpoints.

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	35	37	2	12
Units: ng/mL/(mg/m^2)
geometric mean (geometric coefficient of variation)	4.28 ( 54.6 )	3.97 ( 42.9 )	4.89 ( 99999 )	5.88 ( 47.1 )

No statistical analyses for this end point

Secondary: Parts C1, C2 and C3: Dose Normalized Area Under The Concentration-Time Curve (AUC) from Start of Infusion to The 4 hour Sampling Time After Start of Infusion (AUC0-4h/Dose_mg) of M6620

Top of page

End point title

Parts C1, C2 and C3: Dose Normalized Area Under The Concentration-Time Curve (AUC) from Start of Infusion to The 4 hour Sampling Time After Start of Infusion (AUC0-4h/Dose_mg) of M6620 ^[75]

End point description

Dose normalized was calculated as area under the plasma concentration-time curve from time zero to 4 hour postdose divided by dose. PAS included all subjects who received at least 1 dose of M6620 (with the actual amount > 0 mg and/or the duration of infusion > 0 minutes), and provided at least 1 measurable post-dose concentration. Here, "number of subjects analyzed" signifies those subjects who were evaluable for this endpoint at given time points. Here, "99999" signifies that geometric coefficient of variation was not calculated.

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3 and 4 hours after end of infusion (EOI) on Cycle 1 Day 2 (each cycle is of 21 days)

Notes
[75] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Parts C1, C2 and C3 arms only. For Part A1, A2, B1 and B2 arms we have created separate endpoints.

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	35	34	2	12
Units: ng*h/mL/mg
geometric mean (geometric coefficient of variation)	4.29 ( 37.0 )	4.41 ( 26.1 )	4.11 ( 99999 )	4.24 ( 39.8 )

No statistical analyses for this end point

Secondary: Parts C1, C2 and C3: Dose Normalized Area Under the Concentration-Time Curve (AUC) from Start of Infusion to the 4 hour Sampling Time After Start of Infusion (AUC0-4h/Dose_mg/m^2) of M6620

Top of page

End point title

Parts C1, C2 and C3: Dose Normalized Area Under the Concentration-Time Curve (AUC) from Start of Infusion to the 4 hour Sampling Time After Start of Infusion (AUC0-4h/Dose_mg/m^2) of M6620 ^[76]

End point description

Dose normalized was calculated as area under the plasma concentration-time curve from rom start of infusion to the 4 hour postdose divided by dose. PAS included all subjects who received at least 1 dose of M6620 (with the actual amount > 0 mg and/or the duration of infusion > 0 minutes), and provided at least 1 measurable post-dose concentration. Here, "number of subjects analyzed" signifies those subjects who were evaluable for this endpoint at given time points. Here, "99999" signifies that geometric coefficient of variation was not calculated.

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3 and 4 hours after end of infusion (EOI) on Cycle 1 Day 2 (each cycle is of 21 days)

Notes
[76] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Parts C1, C2 and C3 arms only. For Part A1, A2, B1 and B2 arms we have created separate endpoints.

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	35	34	2	12
Units: ng*h/mL/(mg/m^2)
geometric mean (geometric coefficient of variation)	7.76 ( 36.7 )	7.95 ( 26.4 )	7.40 ( 99999 )	7.71 ( 33.0 )

No statistical analyses for this end point

Secondary: Parts C1, C2 and C3: Dose Normalized Area Under the Concentration-Time Curve (AUC) from Start of Infusion to the 8 hour Sampling Time After Start of Infusion (AUC0-8h/Dose_mg) of M6620

Top of page

End point title

Parts C1, C2 and C3: Dose Normalized Area Under the Concentration-Time Curve (AUC) from Start of Infusion to the 8 hour Sampling Time After Start of Infusion (AUC0-8h/Dose_mg) of M6620 ^[77]

End point description

Dose normalized was calculated as area under the plasma concentration-time curve from time zero to 8 hour postdose divided by dose. PAS included all subjects who received at least 1 dose of M6620 (with the actual amount > 0 mg and/or the duration of infusion > 0 minutes), and provided at least 1 measurable post-dose concentration. Here, "number of subjects analyzed" signifies those subjects who were evaluable for this endpoint at given time points. Here, "99999" signifies that geometric coefficient of variation was not calculated.

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3 and 7 hours after end of infusion (EOI) on Cycle 1 Day 2 (each cycle is of 21 days)

Notes
[77] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Parts C1, C2 and C3 arms only. For Part A1, A2, B1 and B2 arms we have created separate endpoints.

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	3	2	0 ^[78]	2
Units: ng*h/mL/mg
geometric mean (geometric coefficient of variation)	5.43 ( 10.1 )	7.53 ( 99999 )	( )	5.63 ( 99999 )

Notes
[78] - None of the subjects were evaluable at given time points.

No statistical analyses for this end point

Secondary: Parts C1, C2 and C3: Dose Normalized Area Under the Concentration-Time Curve (AUC) from Start of Infusion to the 8 hour Sampling Time After Start of Infusion (AUC0-8h/Dose_mg/m^2) of M6620

Top of page

End point title

Parts C1, C2 and C3: Dose Normalized Area Under the Concentration-Time Curve (AUC) from Start of Infusion to the 8 hour Sampling Time After Start of Infusion (AUC0-8h/Dose_mg/m^2) of M6620 ^[79]

End point description

Dose normalized was calculated as area under the plasma concentration-time curve from time zero to 8 hours postdose divided by dose. PAS included all subjects who received at least 1 dose of M6620 (with the actual amount > 0 mg and/or the duration of infusion > 0 minutes), and provided at least 1 measurable post-dose concentration. Here, "number of subjects analyzed" signifies those subjects who were evaluable for this endpoint at given time points. Here, "99999" signifies that geometric coefficient of variation was not calculated.

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3 and 7 hours after end of infusion (EOI) on Cycle 1 Day 2 (each cycle is of 21 days)

Notes
[79] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Parts C1, C2 and C3 arms only. For Part A1, A2, B1 and B2 arms we have created separate endpoints.

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	3	2	0 ^[80]	2
Units: ng*h/mL/(mg/m^2)
geometric mean (geometric coefficient of variation)	9.54 ( 10.9 )	12.9 ( 99999 )	( )	10.8 ( 99999 )

Notes
[80] - None of the subjects were evaluable at given time points.

No statistical analyses for this end point

Secondary: Parts C1, C2 and C3: Dose Normalized Area Under Concentarion-Time Curve (AUC) from Time Zero to the Last Sampling Time (tlast) (AUC0-t/Dose_mg) of M6620

Top of page

End point title

Parts C1, C2 and C3: Dose Normalized Area Under Concentarion-Time Curve (AUC) from Time Zero to the Last Sampling Time (tlast) (AUC0-t/Dose_mg) of M6620 ^[81]

End point description

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3, and 7 hours after end of infusion (EOI) on Cycle 1 Day 2 (each cycle is of 21 days)

Notes
[81] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Parts C1, C2 and C3 arms only. For Part A1, A2, B1 and B2 arms we have created separate endpoints.

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	35	37	2	12
Units: ng*h/mL/mg
geometric mean (geometric coefficient of variation)	4.47 ( 36.3 )	4.36 ( 30.6 )	3.62 ( 99999 )	4.47 ( 41.7 )

No statistical analyses for this end point

Secondary: Parts C1, C2 and C3: Dose Normalized Area Under Concentarion-Time Curve (AUC) from Time Zero to the Last Sampling Time (tlast) (AUC0-t/Dose_mg/m^2) of M6620

Top of page

End point title

Parts C1, C2 and C3: Dose Normalized Area Under Concentarion-Time Curve (AUC) from Time Zero to the Last Sampling Time (tlast) (AUC0-t/Dose_mg/m^2) of M6620 ^[82]

End point description

End point type

Secondary

End point timeframe

Pre-infusion, 0.5, 1, 2, 3, and 7 hours after end of infusion (EOI) on Cycle 1 Day 2 (each cycle is of 21 days)

Notes
[82] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In this endpoint, we have reported data for Parts C1, C2 and C3 arms only. For Part A1, A2, B1 and B2 arms we have created separate endpoints.

End point values	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Number of subjects analysed	35	37	2	12
Units: ng*h/mL/(mg/m^2)
geometric mean (geometric coefficient of variation)	8.08 ( 36.7 )	7.92 ( 28.8 )	6.51 ( 99999 )	8.12 ( 36.1 )

No statistical analyses for this end point

Adverse events

Top of page

Timeframe for reporting adverse events

Parts A1, A2 and B1: Time from first dose of study treatment up to 4.6 years; Part B2: Time from first dose of study treatment up to 1.6 years; Parts C1, C2 and C3: Time from first dose of study treatment up to 4.3 years.

Adverse event reporting additional description

Non-serious Adverse Event Section: Treatment-Emergent Adverse Events were reported for Parts A1, A2 and B1 and Non-serious Adverse event for Parts B2, C1, C2 and C3 with same threshold frequency (0%).

Assessment type

Non-systematic

Dictionary name

MedDRA

Dictionary version

18,22.1&21

Reporting group title

Part A1: M6620 18 mg/m^2 + Gemcitabine 875 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 36 mg/m^2 + Gemcitabine 875 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 60 mg/m^2 + Gemcitabine 875 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 72 mg/m^2 + Gemcitabine 875 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 90 mg/m^2 + Gemcitabine 500 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 140 mg/m^2 + Gemcitabine 500 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 210 mg/m^2 + Gemcitabine 500 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 210 mg/m^2 + Gemcitabine 750 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 210 mg/m^2 + Gemcitabine 875 mg/m^2

Reporting group description

Reporting group title

Part A1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2

Reporting group description

Reporting group title

Part A2: M6620 90 mg/m^2 + Gemcitabine + Cisplatin

Reporting group description

Subjects received intravenous infusion of M6620 at dose of 90 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine at a dose of 875 mg/m^2 on Days 1 and 8 and Cisplatin at a dose of 60 mg/m^2 on Day 1, of a 21-day cycle up to 41 weeks.

Reporting group title

Part A2: M6620 120 mg/m^2 + Gemcitabine + Cisplatin

Reporting group description

Subjects received intravenous infusion of M6620 at dose of 120 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Gemcitabine at a dose of 875 mg/m^2 on Days 1 and 8 and Cisplatin at a dose of 60 mg/m^2 on Day 1, of a 21-day cycle up to 41 weeks.

Reporting group title

Part B1: M6620 140 mg/m^2

Reporting group description

Subjects received intravenous infusion of M6620 at dose of 140 mg/m^2 approximately for 24 hours later on Days 2 and 9 of a 21-day cycle up to 74 weeks.

Reporting group title

Part B1: M6620 90 mg/m^2 + Cisplatin 40 mg/m^2

Reporting group description

Subjects received intravenous infusion of M6620 at dose of 90 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Cisplatin at a dose of 40 mg/m^2 on Day 1, of a 21-day cycle up to 74 weeks.

Reporting group title

Part B1: M6620 140 mg/m^2 + Cisplatin 40 mg/m^2

Reporting group description

Subjects received intravenous infusion of M6620 at dose of 140mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Cisplatin ata dose of 40 mg/m^2 on Day 1 of a 21-day cycle for up to 74 weeks.

Reporting group title

Part B1: M6620 210 mg/m^2 + Cisplatin 40 mg/m^2

Reporting group description

Subjects received intravenous infusion of M6620 at dose of 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Cisplatin at a dose of 40 mg/m^2 on Day 1 of a 21-day cycle up to 74 weeks.

Reporting group title

Part B1: M6620 210 mg/m^2 + Cisplatin 60 mg/m^2

Reporting group description

Reporting group title

Part B1: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2

Reporting group description

Reporting group title

Part B1: M6620 210 mg/m^2 + Cisplatin 75 mg/m^2

Reporting group description

Subjects received intravenous infusion of M6620 at dose of 210 mg/m^2 approximately for 24 hours later on Days 2 and 9 in combination with Cisplatin at a dose of 75 mg/m^2 on Day 1 of a 21-day cycle up to 74 weeks.

Reporting group title

Part B2: M6620 60 mg/m^2 + Irinotecan 180 mg/m^2

Reporting group description

Subjects received intravenous infusion of M6620 at a dose of 60 mg/m^2, in combination with irinotecan at a dose of 180 mg/m^2 (over 90 minutes) on Days 1 and 15 of a 28-day cycle up to 72 weeks.

Reporting group title

Part B2: M6620 90 mg/m^2 + Irinotecan 180 mg/m^2

Reporting group description

Subjects received intravenous infusion of M6620 at a dose of 90 mg/m^2, in combination with irinotecan at a dose of 180 mg/m^2 (over 90 minutes) on Days 1 and 15 of a 28-day cycle up to 72 weeks.

Reporting group title

Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2

Reporting group description

Reporting group title

Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2

Reporting group description

Reporting group title

Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2

Reporting group description

Reporting group title

Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL

Reporting group description

Subjects with platinum-resistant advanced SCLC received intravenous infusion of M6620 at a dose of 90 mg/m^2 on Days 2 and 9 in combination with Carboplatin area under concentration-time curve (AUC) at a dose of 5 milligrams.minute per milliliter on Day 1 of a 21-day cycle up to 27 weeks.

Part A1: M6620 18 mg/m^2 + Gemcitabine 875 mg/m^2

Part A1: M6620 36 mg/m^2 + Gemcitabine 875 mg/m^2

Part A1: M6620 60 mg/m^2 + Gemcitabine 875 mg/m^2

Part A1: M6620 72 mg/m^2 + Gemcitabine 875 mg/m^2

Part A1: M6620 90 mg/m^2 + Gemcitabine 500 mg/m^2

Part A1: M6620 140 mg/m^2 + Gemcitabine 500 mg/m^2

Part A1: M6620 210 mg/m^2 + Gemcitabine 500 mg/m^2

Part A1: M6620 210 mg/m^2 + Gemcitabine 750 mg/m^2

Part A1: M6620 210 mg/m^2 + Gemcitabine 875 mg/m^2

Part A1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2

Part A2: M6620 90 mg/m^2 + Gemcitabine + Cisplatin

Part A2: M6620 120 mg/m^2 + Gemcitabine + Cisplatin

Part B1: M6620 140 mg/m^2

Part B1: M6620 90 mg/m^2 + Cisplatin 40 mg/m^2

Part B1: M6620 140 mg/m^2 + Cisplatin 40 mg/m^2

Part B1: M6620 210 mg/m^2 + Cisplatin 40 mg/m^2

Part B1: M6620 210 mg/m^2 + Cisplatin 60 mg/m^2

Part B1: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2

Part B1: M6620 210 mg/m^2 + Cisplatin 75 mg/m^2

Part B2: M6620 60 mg/m^2 + Irinotecan 180 mg/m^2

Part B2: M6620 90 mg/m^2 + Irinotecan 180 mg/m^2

Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2

Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2

Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2

Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL

Total subjects affected by serious adverse events

subjects affected / exposed

2 / 3 (66.67%)

0 / 3 (0.00%)

2 / 4 (50.00%)

4 / 7 (57.14%)

3 / 6 (50.00%)

5 / 8 (62.50%)

2 / 3 (66.67%)

1 / 3 (33.33%)

3 / 7 (42.86%)

2 / 6 (33.33%)

3 / 6 (50.00%)

2 / 2 (100.00%)

1 / 4 (25.00%)

2 / 3 (66.67%)

0 / 3 (0.00%)

0 / 4 (0.00%)

4 / 10 (40.00%)

3 / 7 (42.86%)

2 / 3 (66.67%)

1 / 5 (20.00%)

2 / 3 (66.67%)

24 / 38 (63.16%)

15 / 47 (31.91%)

0 / 2 (0.00%)

3 / 13 (23.08%)

number of deaths (all causes)

number of deaths resulting from adverse events

Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Metastases to central nervous system

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

1 / 4 (25.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Brain neoplasm

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

1 / 7 (14.29%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Metastases to liver

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

1 / 1

0 / 0

Non-small cell lung cancer

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

1 / 7 (14.29%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

1 / 1

0 / 0

Vascular disorders

Hypovolaemic shock

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

1 / 1

0 / 0

Superior vena cava syndrome

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

1 / 13 (7.69%)

occurrences causally related to treatment / all

0 / 0

0 / 1

deaths causally related to treatment / all

0 / 0

Thrombosis

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Deep vein thrombosis

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

1 / 7 (14.29%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

General disorders and administration site conditions

Pyrexia

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

1 / 6 (16.67%)

3 / 8 (37.50%)

0 / 3 (0.00%)

0 / 7 (0.00%)

2 / 6 (33.33%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

1 / 7 (14.29%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

2 / 38 (5.26%)

2 / 47 (4.26%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

3 / 3

0 / 0

2 / 2

0 / 0

0 / 1

0 / 0

2 / 2

0 / 0

deaths causally related to treatment / all

0 / 0

Influenza like illness

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

1 / 8 (12.50%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Chills

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

1 / 47 (2.13%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Malaise

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Non-cardiac chest pain

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

2 / 47 (4.26%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 2

0 / 0

deaths causally related to treatment / all

0 / 0

Asthenia

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

1 / 3 (33.33%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Immune system disorders

Hypersensitivity

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

1 / 8 (12.50%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

1 / 7 (14.29%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Reproductive system and breast disorders

Breast haematoma

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

1 / 47 (2.13%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Respiratory, thoracic and mediastinal disorders

Dyspnoea

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

1 / 2 (50.00%)

0 / 4 (0.00%)

1 / 3 (33.33%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

4 / 38 (10.53%)

2 / 47 (4.26%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

0 / 1

0 / 0

0 / 4

0 / 2

0 / 0

deaths causally related to treatment / all

0 / 0

Hypoxia

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

1 / 2 (50.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

1 / 10 (10.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

2 / 47 (4.26%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

0 / 1

0 / 0

1 / 2

0 / 0

deaths causally related to treatment / all

0 / 0

Pleural effusion

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

1 / 2 (50.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

1 / 47 (2.13%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Chronic obstructive pulmonary disease

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Haemoptysis

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

1 / 1

0 / 0

Pulmonary embolism

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

1 / 6 (16.67%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

1 / 47 (2.13%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

1 / 1

0 / 0

Pulmonary oedema

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

1 / 47 (2.13%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Respiratory failure

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Stridor

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Atelectasis

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

1 / 6 (16.67%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Pleuritic pain

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

1 / 7 (14.29%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Investigations

Alanine aminotransferase increased

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

1 / 10 (10.00%)

0 / 7 (0.00%)

1 / 3 (33.33%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Aspartate aminotransferase increased

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

1 / 10 (10.00%)

0 / 7 (0.00%)

1 / 3 (33.33%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Body temperature increased

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

1 / 7 (14.29%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Injury, poisoning and procedural complications

Infusion related reaction

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

1 / 10 (10.00%)

1 / 7 (14.29%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

1 / 47 (2.13%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Allergic transfusion reaction

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

1 / 7 (14.29%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Cardiac disorders

Atrial flutter

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

cardiac arrest

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

1 / 1

0 / 0

Left ventricular hypertrophy

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

1 / 8 (12.50%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Pericardial effusion

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

1 / 3 (33.33%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Nervous system disorders

Serotonin syndrome

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

1 / 6 (16.67%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Cerebrovascular accident

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Hemiparesis

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Seizure

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

1 / 13 (7.69%)

occurrences causally related to treatment / all

0 / 0

0 / 1

deaths causally related to treatment / all

0 / 0

Blood and lymphatic system disorders

Anaemia

subjects affected / exposed

0 / 3 (0.00%)

1 / 4 (25.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

1 / 6 (16.67%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

2 / 38 (5.26%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

1 / 1

0 / 0

2 / 2

0 / 0

deaths causally related to treatment / all

0 / 0

Febrile neutropenia

subjects affected / exposed

0 / 3 (0.00%)

1 / 4 (25.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

1 / 2 (50.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

2 / 47 (4.26%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

1 / 1

0 / 0

2 / 2

0 / 0

deaths causally related to treatment / all

0 / 0

Neutropenia

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

1 / 2 (50.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

1 / 47 (2.13%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Thrombocytopenia

subjects affected / exposed

0 / 3 (0.00%)

1 / 4 (25.00%)

1 / 7 (14.29%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

1 / 6 (16.67%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

3 / 38 (7.89%)

1 / 47 (2.13%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

1 / 1

0 / 0

3 / 3

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Thrombotic thrombocytopenic purpura

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

1 / 13 (7.69%)

occurrences causally related to treatment / all

0 / 0

1 / 1

deaths causally related to treatment / all

0 / 0

Eye disorders

Diplopia

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

1 / 47 (2.13%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Gastrointestinal disorders

Abdominal pain

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

1 / 10 (10.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

1 / 3 (33.33%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Diarrhoea

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

1 / 7 (14.29%)

0 / 3 (0.00%)

0 / 5 (0.00%)

2 / 3 (66.67%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

2 / 2

0 / 0

deaths causally related to treatment / all

0 / 0

Small intestine obstruction

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

1 / 3 (33.33%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Ascites

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Nausea

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

1 / 5 (20.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

2 / 47 (4.26%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

0 / 2

0 / 0

deaths causally related to treatment / all

0 / 0

Rectal haemorrhage

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Vomiting

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

1 / 6 (16.67%)

1 / 8 (12.50%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

2 / 38 (5.26%)

3 / 47 (6.38%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

1 / 2

3 / 3

0 / 0

deaths causally related to treatment / all

0 / 0

Colitis

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

1 / 5 (20.00%)

1 / 3 (33.33%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Hepatobiliary disorders

Portal vein thrombosis

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

1 / 6 (16.67%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Skin and subcutaneous tissue disorders

Rash erythematous

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Renal and urinary disorders

Acute kidney injury

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

1 / 6 (16.67%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

1 / 47 (2.13%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Hydronephrosis

subjects affected / exposed

1 / 3 (33.33%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Musculoskeletal and connective tissue disorders

Flank pain

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

1 / 3 (33.33%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Back pain

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Musculoskeletal pain

subjects affected / exposed

0 / 3 (0.00%)

1 / 4 (25.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

1 / 3 (33.33%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

0 / 1

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Muscular weakness

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

1 / 47 (2.13%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Pathological fracture

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

1 / 7 (14.29%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Infections and infestations

Cellulitis

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

1 / 8 (12.50%)

0 / 3 (0.00%)

1 / 7 (14.29%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

0 / 1

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Escherichia sepsis

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

1 / 3 (33.33%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Infection

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

1 / 3 (33.33%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Lower respiratory tract infection

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

1 / 7 (14.29%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

4 / 38 (10.53%)

1 / 47 (2.13%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

1 / 4

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

1 / 1

0 / 0

Oral candidiasis

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

1 / 6 (16.67%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Pelvic infection

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

1 / 3 (33.33%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Pneumonia

subjects affected / exposed

1 / 3 (33.33%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

2 / 38 (5.26%)

1 / 47 (2.13%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 1

0 / 0

1 / 2

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Sepsis

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

1 / 3 (33.33%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

2 / 38 (5.26%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

1 / 2

0 / 0

deaths causally related to treatment / all

0 / 0

Skin infection

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

1 / 10 (10.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Gastrointestinal infection

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Lung infection

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

1 / 47 (2.13%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Mastoiditis

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

1 / 47 (2.13%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Otitis media acute

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

1 / 47 (2.13%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Abdominal sepsis

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

1 / 3 (33.33%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Metabolism and nutrition disorders

Dehydration

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

1 / 6 (16.67%)

0 / 8 (0.00%)

0 / 3 (0.00%)

1 / 7 (14.29%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

1 / 3 (33.33%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

1 / 1

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Hyponatraemia

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

1 / 7 (14.29%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

0 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Failure to thrive

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

0 / 38 (0.00%)

0 / 47 (0.00%)

0 / 2 (0.00%)

1 / 13 (7.69%)

occurrences causally related to treatment / all

0 / 0

0 / 1

deaths causally related to treatment / all

0 / 0

1 / 1

Hypokalaemia

subjects affected / exposed

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 8 (0.00%)

0 / 3 (0.00%)

0 / 7 (0.00%)

0 / 6 (0.00%)

0 / 2 (0.00%)

0 / 4 (0.00%)

0 / 3 (0.00%)

0 / 4 (0.00%)

0 / 10 (0.00%)

0 / 7 (0.00%)

0 / 3 (0.00%)

0 / 5 (0.00%)

0 / 3 (0.00%)

1 / 38 (2.63%)

0 / 47 (0.00%)

0 / 2 (0.00%)

0 / 13 (0.00%)

occurrences causally related to treatment / all

0 / 0

1 / 1

0 / 0

deaths causally related to treatment / all

0 / 0

Frequency threshold for reporting non-serious adverse events: 0%

Non-serious adverse events	Part A1: M6620 18 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 36 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 60 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 72 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 90 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 140 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 500 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 750 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 875 mg/m^2	Part A1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part A2: M6620 90 mg/m^2 + Gemcitabine + Cisplatin	Part A2: M6620 120 mg/m^2 + Gemcitabine + Cisplatin	Part B1: M6620 140 mg/m^2	Part B1: M6620 90 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 140 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 40 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 60 mg/m^2	Part B1: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part B1: M6620 210 mg/m^2 + Cisplatin 75 mg/m^2	Part B2: M6620 60 mg/m^2 + Irinotecan 180 mg/m^2	Part B2: M6620 90 mg/m^2 + Irinotecan 180 mg/m^2	Part C1: M6620 210 mg/m^2 + Gemcitabine 1000 mg/m^2	Part C2: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 140 mg/m^2 + Cisplatin 75 mg/m^2	Part C3: M6620 90 mg/m^2 + Carboplatin AUC 5 mg∙min/mL
Total subjects affected by non serious adverse events
subjects affected / exposed	3 / 3 (100.00%)	3 / 3 (100.00%)	4 / 4 (100.00%)	6 / 7 (85.71%)	6 / 6 (100.00%)	8 / 8 (100.00%)	3 / 3 (100.00%)	3 / 3 (100.00%)	7 / 7 (100.00%)	6 / 6 (100.00%)	6 / 6 (100.00%)	2 / 2 (100.00%)	3 / 4 (75.00%)	3 / 3 (100.00%)	3 / 3 (100.00%)	3 / 4 (75.00%)	10 / 10 (100.00%)	7 / 7 (100.00%)	3 / 3 (100.00%)	5 / 5 (100.00%)	3 / 3 (100.00%)	37 / 38 (97.37%)	47 / 47 (100.00%)	2 / 2 (100.00%)	13 / 13 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non-small cell lung cancer
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Tumour pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Metastases to central nervous system
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Brain neoplasm
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Metastases to peritoneum
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Vascular disorders
Deep vein thrombosis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 7 (28.57%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	3 / 47 (6.38%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	2	3	0	0
Flushing
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	1 / 8 (12.50%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 4 (25.00%)	2 / 10 (20.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	5 / 47 (10.64%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	1	1	1	0	0	0	0	0	0	1	0	1	2	0	1	0	0	0	5	0	0
Hot flush
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	4 / 47 (8.51%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0	1
Hypertension
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	2 / 6 (33.33%)	1 / 8 (12.50%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	1 / 10 (10.00%)	2 / 7 (28.57%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	3 / 38 (7.89%)	4 / 47 (8.51%)	0 / 2 (0.00%)	2 / 13 (15.38%)
occurrences all number	0	0	0	0	2	1	0	1	0	0	0	0	1	0	1	0	1	2	0	0	0	3	4	0	2
Jugular vein thrombosis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	1 / 2 (50.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Vascular compression
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	1 / 2 (50.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Hypotension
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 4 (25.00%)	1 / 7 (14.29%)	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)	1 / 2 (50.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	1 / 10 (10.00%)	2 / 7 (28.57%)	1 / 3 (33.33%)	0 / 5 (0.00%)	1 / 3 (33.33%)	1 / 38 (2.63%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	1	1	1	1	0	0	0	0	1	0	1	0	0	0	1	1	2	1	0	1	1	1	0	0
White coat hypertension
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Lymphoedema
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Peripheral coldness
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Phlebitis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0
Embolism
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Subclavian vein thrombosis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Superior vena cava occlusion
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Thrombophlebitis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
Vein disorder
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
General disorders and administration site conditions
Asthenia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	3 / 38 (7.89%)	1 / 47 (2.13%)	0 / 2 (0.00%)	2 / 13 (15.38%)
occurrences all number	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	3	1	0	0
Chills
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	4 / 38 (10.53%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	4	2	0	0
Fatigue
subjects affected / exposed	2 / 3 (66.67%)	2 / 3 (66.67%)	1 / 4 (25.00%)	2 / 7 (28.57%)	3 / 6 (50.00%)	6 / 8 (75.00%)	3 / 3 (100.00%)	3 / 3 (100.00%)	6 / 7 (85.71%)	4 / 6 (66.67%)	6 / 6 (100.00%)	2 / 2 (100.00%)	0 / 4 (0.00%)	3 / 3 (100.00%)	1 / 3 (33.33%)	2 / 4 (50.00%)	4 / 10 (40.00%)	4 / 7 (57.14%)	3 / 3 (100.00%)	2 / 5 (40.00%)	2 / 3 (66.67%)	21 / 38 (55.26%)	32 / 47 (68.09%)	2 / 2 (100.00%)	5 / 13 (38.46%)
occurrences all number	2	2	1	2	3	6	3	3	6	4	6	2	0	3	1	2	4	4	3	2	2	21	32	2	5
Influenza like illness
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	2 / 8 (25.00%)	1 / 3 (33.33%)	2 / 3 (66.67%)	2 / 7 (28.57%)	4 / 6 (66.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	1	0	0	0	1	2	1	2	2	4	0	0	0	1	0	1	0	0	0	0	0	2	1	0	0
Injection site reaction
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	2 / 13 (15.38%)
occurrences all number	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2
Malaise
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non-cardiac chest pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	4 / 38 (10.53%)	6 / 47 (12.77%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	6	0	0
Oedema peripheral
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	2 / 8 (25.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)	1 / 6 (16.67%)	1 / 6 (16.67%)	1 / 2 (50.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	2 / 7 (28.57%)	1 / 3 (33.33%)	1 / 5 (20.00%)	0 / 3 (0.00%)	6 / 38 (15.79%)	4 / 47 (8.51%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	1	0	1	2	0	1	0	1	1	1	0	0	0	0	1	2	1	1	0	6	4	0	0
Pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0
Peripheral swelling
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	3 / 47 (6.38%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	1	0	1	3	0	0
Pyrexia
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	2 / 4 (50.00%)	1 / 7 (14.29%)	3 / 6 (50.00%)	4 / 8 (50.00%)	0 / 3 (0.00%)	2 / 3 (66.67%)	2 / 7 (28.57%)	3 / 6 (50.00%)	2 / 6 (33.33%)	1 / 2 (50.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	1 / 3 (33.33%)	0 / 5 (0.00%)	0 / 3 (0.00%)	12 / 38 (31.58%)	7 / 47 (14.89%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	1	2	1	3	4	0	2	2	3	2	1	0	1	0	0	0	1	1	0	0	12	7	0	1
Face oedema
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 4 (25.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	1	0	0	0	0	0
Infusion site extravasation
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0
Infusion site reaction
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Infusion site erythema
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	2 / 10 (20.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	2	0	0	0	0	1	0	0	0
Axillary pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Catheter site pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Catheter site rash
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Catheter site related reaction
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
Chest discomfort
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Chest pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Device occlusion
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hypothermia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Infusion site discomfort
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Infusion site rash
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Injection site phlebitis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Mucosal inflammation
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Catheter site pruritus
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Infusion site pruritus
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0
Catheter site bruise
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Catheter site induration
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Catheter site inflammation
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Extravasation
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
Injection site mass
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Injection site pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Injection site pruritus
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Localised oedema
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Thirst
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Immune system disorders
Hypersensitivity
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0
Drug hypersensitivity
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
Seasonal allergy
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Reproductive system and breast disorders
Balanoposthitis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Prostatism
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Testicular pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Testicular swelling
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Breast pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
Menstruation irregular
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Metrorrhagia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Pelvic pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Vaginal haemorrhage
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Respiratory, thoracic and mediastinal disorders
Cough
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	2 / 7 (28.57%)	2 / 6 (33.33%)	3 / 8 (37.50%)	1 / 3 (33.33%)	2 / 3 (66.67%)	1 / 7 (14.29%)	3 / 6 (50.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 10 (0.00%)	2 / 7 (28.57%)	0 / 3 (0.00%)	3 / 5 (60.00%)	0 / 3 (0.00%)	5 / 38 (13.16%)	8 / 47 (17.02%)	1 / 2 (50.00%)	2 / 13 (15.38%)
occurrences all number	1	0	0	2	2	3	1	2	1	3	1	0	0	1	1	0	0	2	0	3	0	5	8	1	2
Epistaxis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	1	0	2	1	0	0
Haemoptysis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	2 / 38 (5.26%)	0 / 47 (0.00%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	2	0	0	1
Nasal congestion
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	2 / 5 (40.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	2 / 47 (4.26%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	2	0	1
Productive cough
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	1 / 47 (2.13%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	1	0	1
Wheezing
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	1 / 3 (33.33%)	2 / 38 (5.26%)	1 / 47 (2.13%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	1	0	1
Dyspnoea
subjects affected / exposed	0 / 3 (0.00%)	2 / 3 (66.67%)	0 / 4 (0.00%)	2 / 7 (28.57%)	3 / 6 (50.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	3 / 6 (50.00%)	0 / 6 (0.00%)	1 / 2 (50.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	2 / 5 (40.00%)	1 / 3 (33.33%)	14 / 38 (36.84%)	7 / 47 (14.89%)	0 / 2 (0.00%)	2 / 13 (15.38%)
occurrences all number	0	2	0	2	3	0	1	0	0	3	0	1	0	1	0	0	0	0	0	2	1	14	7	0	2
Hypoxia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 2 (50.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	1	0	0	1	0	0	0	0
Oropharyngeal pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	1	0	0
Rhinorrhoea
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	0
Laryngeal oedema
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Pleural effusion
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 2 (50.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0
Pleuritic pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	2 / 7 (28.57%)	2 / 6 (33.33%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dyspnoea exertional
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0
Pulmonary embolism
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
Asthma
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Atelectasis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Dysphonia
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	14 / 38 (36.84%)	7 / 47 (14.89%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	14	7	0	0
Hiccups
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	1 / 3 (33.33%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	1	0	0
Nasal ulcer
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sputum increased
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Upper-airway cough syndrome
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	2	0	0
Rhinitis allergic
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	0	0
Sleep apnoea syndrome
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Pneumonitis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Rales
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Respiratory failure
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Psychiatric disorders
Anxiety
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	2 / 38 (5.26%)	6 / 47 (12.77%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	0	0	1	2	6	0	0
Depression
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	2 / 13 (15.38%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2
Insomnia
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	2 / 3 (66.67%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	3 / 47 (6.38%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	1	0	0	0	1	2	0	0	1	0	0	0	0	1	1	0	0	0	0	0	2	3	0	1
Depressed mood
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)	1 / 2 (50.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Hallucination
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Adjustment disorder with depressed mood
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Dissociation
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Sleep disorder
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Investigations
Alanine aminotransferase increased
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	2 / 4 (50.00%)	1 / 7 (14.29%)	4 / 6 (66.67%)	5 / 8 (62.50%)	2 / 3 (66.67%)	2 / 3 (66.67%)	4 / 7 (57.14%)	4 / 6 (66.67%)	2 / 6 (33.33%)	1 / 2 (50.00%)	1 / 4 (25.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 4 (0.00%)	1 / 10 (10.00%)	1 / 7 (14.29%)	1 / 3 (33.33%)	0 / 5 (0.00%)	1 / 3 (33.33%)	10 / 38 (26.32%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	1	0	2	1	4	5	2	2	4	4	2	1	1	1	1	0	1	1	1	0	1	10	1	0	0
Aspartate aminotransferase increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 4 (50.00%)	1 / 7 (14.29%)	4 / 6 (66.67%)	3 / 8 (37.50%)	1 / 3 (33.33%)	2 / 3 (66.67%)	3 / 7 (42.86%)	3 / 6 (50.00%)	2 / 6 (33.33%)	1 / 2 (50.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	3 / 10 (30.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)	3 / 3 (100.00%)	11 / 38 (28.95%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	2	1	4	3	1	2	3	3	2	1	1	0	1	0	3	0	1	0	3	11	0	0	0
Blood alkaline phosphatase increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	2 / 7 (28.57%)	1 / 6 (16.67%)	3 / 8 (37.50%)	3 / 3 (100.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	2 / 6 (33.33%)	1 / 6 (16.67%)	1 / 2 (50.00%)	1 / 4 (25.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	1 / 3 (33.33%)	2 / 38 (5.26%)	1 / 47 (2.13%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	2	1	3	3	0	0	2	1	1	1	1	1	0	0	0	0	1	1	2	1	0	1
Blood bilirubin increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	1 / 6 (16.67%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 7 (14.29%)	1 / 6 (16.67%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	1	1	0	1	0	1	1	1	0	0	0	0	0	0	0	0	0	1	0	0	0	1
Blood creatinine increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	3 / 38 (7.89%)	1 / 47 (2.13%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	1	0	1	1	0	0	1	0	0	1	0	0	0	0	0	0	1	3	1	0	1
Gamma-glutamyltransferase increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 7 (0.00%)	1 / 6 (16.67%)	1 / 6 (16.67%)	1 / 2 (50.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	2 / 47 (4.26%)	1 / 2 (50.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	1	1	0	1	1	1	0	0	0	0	0	0	0	0	0	2	2	1	0
Lipase increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
Neutrophil count decreased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	2 / 7 (28.57%)	1 / 3 (33.33%)	2 / 5 (40.00%)	1 / 3 (33.33%)	1 / 38 (2.63%)	4 / 47 (8.51%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	2	1	2	1	1	4	0	1
Platelet count decreased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	2 / 7 (28.57%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	3 / 38 (7.89%)	2 / 47 (4.26%)	0 / 2 (0.00%)	3 / 13 (23.08%)
occurrences all number	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	2	0	0	0	3	2	0	3
Weight decreased
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)	2 / 5 (40.00%)	1 / 3 (33.33%)	1 / 38 (2.63%)	4 / 47 (8.51%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	1	0	0	0	0	1	0	0	1	0	0	0	0	0	1	0	0	0	1	2	1	1	4	0	0
White blood cell count decreased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)	1 / 2 (50.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	3 / 7 (42.86%)	1 / 3 (33.33%)	2 / 5 (40.00%)	1 / 3 (33.33%)	8 / 38 (21.05%)	4 / 47 (8.51%)	0 / 2 (0.00%)	3 / 13 (23.08%)
occurrences all number	0	0	0	1	1	0	0	0	0	1	0	1	0	0	0	0	0	3	1	2	1	8	4	0	3
Electrocardiogram QT prolonged
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0
Lymphocyte count decreased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	2 / 5 (40.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	1	0	0	1	0	0	0	1	1	0	2	0	0	2	0	0
Platelet count increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)	1 / 7 (14.29%)	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Blood lactate dehydrogenase increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	2 / 7 (28.57%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
Transaminases increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 7 (0.00%)	2 / 6 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	1	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Blood calcium decreased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
White blood cell count increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Bacterial test positive
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Blood calcium increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Blood magnesium decreased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Blood phosphorus decreased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Blood sodium decreased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Blood urea increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Blood uric acid increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Body temperature increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Eastern Cooperative Oncology Group performance status worsened
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Neutrophil count increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Blood creatine phosphokinase increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Fibrin D dimer increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Prothrombin time prolonged
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Respiratory rate increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0
Weight increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	1 / 10 (10.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0	0
Blood Chloride Decreased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0
Blood albumin decreased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Blood cholesterol increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Amylase increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
Blood pressure decreased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Glomerular filtration rate decreased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Glomerular filtration rate increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Haemoglobin decreased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Troponin increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Injury, poisoning and procedural complications
Fall
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	1 / 47 (2.13%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	2	1	0	1
Infusion related reaction
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	1 / 10 (10.00%)	1 / 7 (14.29%)	1 / 3 (33.33%)	1 / 5 (20.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	7 / 47 (14.89%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	1	1	1	1	0	2	7	0	1
Contusion
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0
Muscle strain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Allergic transfusion reaction
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Animal bite
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Skin abrasion
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Procedural headache
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Procedural pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
Spinal fracture
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Tooth fracture
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Cardiac disorders
Palpitations
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	3 / 47 (6.38%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	3	0	0
Sinus bradycardia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	3 / 47 (6.38%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0	0
Sinus tachycardia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)	1 / 3 (33.33%)	3 / 38 (7.89%)	3 / 47 (6.38%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	3	3	0	0
Tachycardia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	3 / 38 (7.89%)	1 / 47 (2.13%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	3	1	0	1
Extrasystoles
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Left ventricular hypertrophy
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pericardial effusion
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Atrial fibrillation
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Ventricular arrhythmia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Nervous system disorders
Amnesia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Balance disorder
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Dizziness
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 4 (25.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 7 (28.57%)	0 / 6 (0.00%)	2 / 6 (33.33%)	1 / 2 (50.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 4 (75.00%)	1 / 10 (10.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	3 / 38 (7.89%)	11 / 47 (23.40%)	0 / 2 (0.00%)	2 / 13 (15.38%)
occurrences all number	0	1	1	0	1	1	0	0	2	0	2	1	0	0	0	3	1	1	0	0	0	3	11	0	2
Dysgeusia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	9 / 47 (19.15%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	1	1	0	0	0	1	0	1	0	0	0	0	0	1	9	0	0
Headache
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 4 (50.00%)	1 / 7 (14.29%)	1 / 6 (16.67%)	4 / 8 (50.00%)	2 / 3 (66.67%)	2 / 3 (66.67%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)	1 / 2 (50.00%)	0 / 4 (0.00%)	2 / 3 (66.67%)	1 / 3 (33.33%)	2 / 4 (50.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	8 / 38 (21.05%)	18 / 47 (38.30%)	0 / 2 (0.00%)	4 / 13 (30.77%)
occurrences all number	0	0	2	1	1	4	2	2	0	1	0	1	0	2	1	2	0	1	0	0	1	8	18	0	4
Neuropathy peripheral
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	8 / 47 (17.02%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	1	8	0	0
Paraesthesia
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	4 / 47 (8.51%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	1	0	0	1	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	4	0	0
Peripheral sensory neuropathy
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	8 / 47 (17.02%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	8	0	1
Neuralgia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0
Poor quality sleep
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Post herpetic neuralgia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Lethargy
subjects affected / exposed	0 / 3 (0.00%)	2 / 3 (66.67%)	1 / 4 (25.00%)	1 / 7 (14.29%)	2 / 6 (33.33%)	4 / 8 (50.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	1 / 6 (16.67%)	2 / 6 (33.33%)	1 / 2 (50.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	2	1	1	2	4	0	0	1	1	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Neurotoxicity
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Serotonin syndrome
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Parosmia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sciatica
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Somnolence
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
Vocal cord paralysis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Depressed level of consciousness
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Hemiparesis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Peripheral motor neuropathy
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Aphasia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Brain oedema
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Hemiparaesthesia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Hyperaesthesia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Hypoaesthesia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
Memory impairment
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Migraine
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Restless legs syndrome
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
Sinus headache
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Tremor
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
Blood and lymphatic system disorders
Anaemia
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 4 (25.00%)	4 / 7 (57.14%)	2 / 6 (33.33%)	4 / 8 (50.00%)	2 / 3 (66.67%)	3 / 3 (100.00%)	4 / 7 (57.14%)	5 / 6 (83.33%)	2 / 6 (33.33%)	1 / 2 (50.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)	1 / 4 (25.00%)	5 / 10 (50.00%)	6 / 7 (85.71%)	1 / 3 (33.33%)	2 / 5 (40.00%)	2 / 3 (66.67%)	19 / 38 (50.00%)	19 / 47 (40.43%)	1 / 2 (50.00%)	6 / 13 (46.15%)
occurrences all number	0	1	1	4	2	4	2	3	4	5	2	1	0	1	1	1	5	6	1	2	2	19	19	1	6
Leukopenia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 7 (14.29%)	3 / 6 (50.00%)	1 / 6 (16.67%)	1 / 2 (50.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	1 / 10 (10.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	3 / 38 (7.89%)	5 / 47 (10.64%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	1	1	3	1	1	0	0	0	1	1	1	0	0	0	3	5	0	0
Neutropenia
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	1 / 4 (25.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	2 / 8 (25.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)	2 / 7 (28.57%)	4 / 6 (66.67%)	4 / 6 (66.67%)	1 / 2 (50.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	6 / 10 (60.00%)	1 / 7 (14.29%)	2 / 3 (66.67%)	1 / 5 (20.00%)	1 / 3 (33.33%)	11 / 38 (28.95%)	29 / 47 (61.70%)	1 / 2 (50.00%)	3 / 13 (23.08%)
occurrences all number	1	1	1	0	1	2	1	1	2	4	4	1	0	0	0	1	6	1	2	1	1	11	29	1	3
Thrombocytopenia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 4 (50.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	2 / 8 (25.00%)	2 / 3 (66.67%)	1 / 3 (33.33%)	1 / 7 (14.29%)	3 / 6 (50.00%)	2 / 6 (33.33%)	1 / 2 (50.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	2 / 10 (20.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	12 / 38 (31.58%)	9 / 47 (19.15%)	1 / 2 (50.00%)	6 / 13 (46.15%)
occurrences all number	0	0	2	1	0	2	2	1	1	3	2	1	0	0	0	0	2	1	0	0	0	12	9	1	6
Febrile neutropenia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 2 (50.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Lymphopenia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	1	0	0
Thrombocytosis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Iron deficiency anameia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Increased tendency to bruise
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Leukocytosis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Lymphadenopathy
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Pancytopenia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Ear and labyrinth disorders
Deafness
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	4 / 47 (8.51%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0	0
Ear discomfort
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
Hyperacusis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	1 / 2 (50.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Tinnitus
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 10 (0.00%)	3 / 7 (42.86%)	1 / 3 (33.33%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	21 / 47 (44.68%)	1 / 2 (50.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	0	3	1	0	0	1	21	1	0
External ear inflammation
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Ear pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0
Middle ear inflammation
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hearing impaired
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Hypoacusis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0
Vertigo
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Neurosensory hypoacusis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Eye disorders
Vision blurred
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	2 / 8 (25.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	1 / 10 (10.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	3 / 47 (6.38%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	1	0	0	0	2	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	3	0	0
Visual impairment
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1
Lacrimation increased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Photopsia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Conjunctival haemorrhage
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Eye pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Periorbital oedema
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Eye irritation
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0
Eyelid odema
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Photophobia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0
Diplopia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Eye haemorrhage
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Foreign body sensation in eyes
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Gastrointestinal disorders
Abdominal pain
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 7 (0.00%)	2 / 6 (33.33%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 7 (14.29%)	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	2 / 3 (66.67%)	2 / 4 (50.00%)	1 / 10 (10.00%)	0 / 7 (0.00%)	2 / 3 (66.67%)	2 / 5 (40.00%)	0 / 3 (0.00%)	3 / 38 (7.89%)	5 / 47 (10.64%)	1 / 2 (50.00%)	0 / 13 (0.00%)
occurrences all number	1	0	1	0	2	0	1	0	1	1	0	0	0	0	2	2	1	0	2	2	0	3	5	1	0
Abdominal pain upper
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	1 / 8 (12.50%)	2 / 3 (66.67%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	1 / 6 (16.67%)	1 / 2 (50.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	3 / 47 (6.38%)	1 / 2 (50.00%)	0 / 13 (0.00%)
occurrences all number	1	0	1	0	1	1	2	0	1	0	1	1	0	0	0	0	0	0	0	0	0	0	3	1	0
Constipation
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	2 / 4 (50.00%)	2 / 7 (28.57%)	2 / 6 (33.33%)	2 / 8 (25.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)	3 / 7 (42.86%)	1 / 6 (16.67%)	2 / 6 (33.33%)	1 / 2 (50.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)	1 / 4 (25.00%)	5 / 10 (50.00%)	2 / 7 (28.57%)	1 / 3 (33.33%)	4 / 5 (80.00%)	1 / 3 (33.33%)	6 / 38 (15.79%)	14 / 47 (29.79%)	2 / 2 (100.00%)	4 / 13 (30.77%)
occurrences all number	1	1	2	2	2	2	1	1	3	1	2	1	0	1	1	1	5	2	1	4	1	6	14	2	4
Diarrhoea
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	2 / 4 (50.00%)	2 / 7 (28.57%)	3 / 6 (50.00%)	2 / 8 (25.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)	2 / 7 (28.57%)	1 / 6 (16.67%)	3 / 6 (50.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	2 / 4 (50.00%)	1 / 10 (10.00%)	1 / 7 (14.29%)	2 / 3 (66.67%)	2 / 5 (40.00%)	1 / 3 (33.33%)	5 / 38 (13.16%)	16 / 47 (34.04%)	0 / 2 (0.00%)	2 / 13 (15.38%)
occurrences all number	1	0	2	2	3	2	1	1	2	1	3	0	0	1	0	2	1	1	2	2	1	5	16	0	2
Dyspepsia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)	2 / 7 (28.57%)	1 / 6 (16.67%)	0 / 6 (0.00%)	1 / 2 (50.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	3 / 38 (7.89%)	5 / 47 (10.64%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	1	1	0	0	1	1	2	1	0	1	0	0	0	0	0	1	0	1	0	3	5	0	0
Dysphagia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1
Haemorrhoids
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Nausea
subjects affected / exposed	2 / 3 (66.67%)	2 / 3 (66.67%)	3 / 4 (75.00%)	3 / 7 (42.86%)	3 / 6 (50.00%)	5 / 8 (62.50%)	2 / 3 (66.67%)	3 / 3 (100.00%)	4 / 7 (57.14%)	4 / 6 (66.67%)	5 / 6 (83.33%)	2 / 2 (100.00%)	1 / 4 (25.00%)	2 / 3 (66.67%)	2 / 3 (66.67%)	2 / 4 (50.00%)	4 / 10 (40.00%)	4 / 7 (57.14%)	1 / 3 (33.33%)	3 / 5 (60.00%)	2 / 3 (66.67%)	15 / 38 (39.47%)	39 / 47 (82.98%)	1 / 2 (50.00%)	4 / 13 (30.77%)
occurrences all number	2	2	3	3	3	5	2	3	4	4	5	2	1	2	2	4	4	1	1	3	2	15	39	1	4
Stomatitis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	2 / 7 (28.57%)	0 / 6 (0.00%)	2 / 8 (25.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	2 / 6 (33.33%)	2 / 6 (33.33%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	3 / 38 (7.89%)	6 / 47 (12.77%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	2	0	2	0	0	0	2	2	0	0	0	1	0	0	0	0	0	0	3	6	0	1
Vomiting
subjects affected / exposed	2 / 3 (66.67%)	3 / 3 (100.00%)	3 / 4 (75.00%)	2 / 7 (28.57%)	3 / 6 (50.00%)	2 / 8 (25.00%)	1 / 3 (33.33%)	2 / 3 (66.67%)	2 / 7 (28.57%)	2 / 6 (33.33%)	3 / 6 (50.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)	1 / 4 (25.00%)	2 / 10 (20.00%)	3 / 7 (42.86%)	1 / 3 (33.33%)	2 / 5 (40.00%)	1 / 3 (33.33%)	11 / 38 (28.95%)	28 / 47 (59.57%)	1 / 2 (50.00%)	4 / 13 (30.77%)
occurrences all number	2	3	3	2	3	2	1	2	2	2	3	0	0	1	1	1	2	3	1	2	1	11	28	1	4
Abdominal distension
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	2 / 3 (66.67%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	1 / 3 (33.33%)	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	1	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0
Gastrooesophageal reflux disease
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	1	0	0	0	1	0	1	0	0	1	0	0	0	0	0	1	0	0	1	1	0	0	2	0	0
Haematochezia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0
Oral disorder
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Paraesthesia oral
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Toothache
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0
Rectal haemorrhage
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Retching
subjects affected / exposed	0 / 3 (0.00%)	2 / 3 (66.67%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Abdominal discomfort
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	2 / 6 (33.33%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	1	0	1	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Dry mouth
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	2	0	0
Oral pain
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ascites
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Faeces discoloured
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Gingival bleeding
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Mouth ulceration
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Odynophagia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Salivary hypersecretion
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Lower gastrointestinal haemorrhage
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Flatulence
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Gastritis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0
Small intestine obstruction
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Abdominal pain lower
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Eructation
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Gingival pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
Gingival swelling
alternative dictionary used: MedDRA 18,22.1&21
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Oesophageal obstruction
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Oral dysaesthesia
alternative dictionary used: MedDRA 18,22.1&21
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Tongue ulceration
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Hepatobiliary disorders
Hyperbilirubinaemia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Hepatomegaly
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Portal vein thrombosis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Skin and subcutaneous tissue disorders
Alopecia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	2 / 5 (40.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	7 / 47 (14.89%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	2	0	0	7	0	0
Erythema
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	3 / 47 (6.38%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	1	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	1	3	0	0
Hyperhidrosis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	1	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	1
Pruritus
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	2	2	0	0
Rash
subjects affected / exposed	2 / 3 (66.67%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	1 / 6 (16.67%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	7 / 38 (18.42%)	2 / 47 (4.26%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	2	0	0	1	1	0	1	0	1	0	1	0	0	0	0	0	1	0	0	1	0	7	2	0	1
Rash maculo-papular
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0
Swelling face
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	1 / 2 (50.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Nail ridging
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Night sweats
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 4 (25.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Rash erythematous
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	1	0	1	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	1	2	0	0
Decubitus ulcer
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dermatitis acneiform
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0
Dry skin
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Rash pruritic
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Throat irritation
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Cold sweat
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Dermatitis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Dermatitis allergic
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
Petechiae
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Pruritus generalised
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Skin disorder
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Skin ulcer
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Urticaria
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Renal and urinary disorders
Dysuria
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	2 / 47 (4.26%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2	2	0	1
Nocturia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Pollakiuria
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	0	0	0
Acute kidney injury
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	2	0	0
Haematuria
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	0	0
Proteinuria
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	2 / 5 (40.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	2	0	0	2	0	0
Hydronephrosis
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic kidney disease
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Renal impairment
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Urine flow decreased
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Incontinence
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Micturition urgency
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Urinary hesitation
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Urinary incontinence
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Urinary tract pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Musculoskeletal and connective tissue disorders
Arthralgia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	1 / 8 (12.50%)	1 / 3 (33.33%)	0 / 3 (0.00%)	2 / 7 (28.57%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	5 / 38 (13.16%)	5 / 47 (10.64%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	1	1	1	0	2	0	0	0	0	0	0	0	0	0	0	1	0	5	5	0	1
Back pain
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 4 (25.00%)	3 / 7 (42.86%)	1 / 6 (16.67%)	1 / 8 (12.50%)	3 / 3 (100.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)	1 / 5 (20.00%)	0 / 3 (0.00%)	4 / 38 (10.53%)	7 / 47 (14.89%)	0 / 2 (0.00%)	2 / 13 (15.38%)
occurrences all number	1	0	1	3	1	1	3	0	0	0	0	0	0	0	1	0	0	0	1	1	0	4	7	0	2
Muscle spasms
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	4 / 47 (8.51%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	9	1	4	0	0
Musculoskeletal chest pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	4 / 47 (8.51%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4	0	0
Musculoskeletal discomfort
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
Musculoskeletal pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	2 / 3 (66.67%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	3 / 38 (7.89%)	2 / 47 (4.26%)	0 / 2 (0.00%)	2 / 13 (15.38%)
occurrences all number	0	0	1	0	0	1	0	2	0	0	1	0	0	0	0	0	0	0	0	0	0	3	2	0	2
Myalgia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	2 / 8 (25.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 6 (0.00%)	2 / 6 (33.33%)	0 / 2 (0.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	2 / 5 (40.00%)	1 / 3 (33.33%)	2 / 38 (5.26%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	1	2	0	1	0	0	2	0	0	1	0	1	0	0	0	2	1	2	2	0	0
Neck pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	4 / 47 (8.51%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	4	0	0
Pain in extremity
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	2 / 8 (25.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	3 / 38 (7.89%)	4 / 47 (8.51%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	2	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	3	4	0	0
Pain in jaw
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0
Bone pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
Groin pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Myopathy
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pathological fracture
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Flank pain
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0
Muscular weakness
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	2	0	0
Limb discomfort
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Musculoskeletal stiffness
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Soft tissue swelling
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Infections and infestations
Bronchitis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1
Lower respiratory tract infection
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 4 (25.00%)	1 / 7 (14.29%)	2 / 6 (33.33%)	3 / 8 (37.50%)	0 / 3 (0.00%)	1 / 3 (33.33%)	2 / 7 (28.57%)	2 / 6 (33.33%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	7 / 38 (18.42%)	1 / 47 (2.13%)	1 / 2 (50.00%)	0 / 13 (0.00%)
occurrences all number	0	1	1	1	2	3	0	1	2	2	0	0	0	0	0	0	0	0	0	0	0	7	1	1	0
Lung infection
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
Oral candidiasis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	1	0	1	0	2	0	0	0
Pneumonia
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1
Rhinitis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	1 / 6 (16.67%)	2 / 8 (25.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	0 / 47 (0.00%)	0 / 2 (0.00%)	3 / 13 (23.08%)
occurrences all number	0	0	0	1	1	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	3
Upper respiratory tract infection
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)	3 / 6 (50.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	1 / 38 (2.63%)	5 / 47 (10.64%)	1 / 2 (50.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	1	0	3	0	0	0	0	0	0	0	0	0	0	1	1	5	1	0
Urinary tract infection
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	1 / 8 (12.50%)	1 / 3 (33.33%)	0 / 3 (0.00%)	2 / 7 (28.57%)	1 / 6 (16.67%)	2 / 6 (33.33%)	1 / 2 (50.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	2 / 10 (20.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	4 / 38 (10.53%)	9 / 47 (19.15%)	0 / 2 (0.00%)	2 / 13 (15.38%)
occurrences all number	0	0	0	1	0	1	1	0	2	1	2	1	0	1	0	0	2	0	0	0	1	4	9	0	2
Viral upper respiratory tract infection
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Conjunctivitis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0
Herpes zoster
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	0
Localised infection
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0
Oral herpes
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Sinusitis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0
Tooth infection
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Viral infection
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Breast abscess
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Injection site cellulitis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cellulitis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	2 / 8 (25.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	2	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	2	0	0
Chest wall abscess
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Escherichia sepsis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Genital candidiasis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Infected skin ulcer infection
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Lower respiratory tract infection viral
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Nasopharyngitis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Oesophageal candidiasis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Pelvic infection
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Perichondritis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sepsis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Skin infection
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0
Vulvovaginal candidiasis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Bacterial infection
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Catheter site infection
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Clostridium difficile infection
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Device related infection
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Enteritis infectious
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Gingivitis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Influenza
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
Mastitis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Mastoiditis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Otitis media
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Vaginal infection
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Metabolism and nutrition disorders
Decreased appetite
subjects affected / exposed	0 / 3 (0.00%)	2 / 3 (66.67%)	0 / 4 (0.00%)	3 / 7 (42.86%)	1 / 6 (16.67%)	3 / 8 (37.50%)	1 / 3 (33.33%)	1 / 3 (33.33%)	3 / 7 (42.86%)	2 / 6 (33.33%)	1 / 6 (16.67%)	1 / 2 (50.00%)	0 / 4 (0.00%)	3 / 3 (100.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	2 / 3 (66.67%)	1 / 5 (20.00%)	1 / 3 (33.33%)	11 / 38 (28.95%)	10 / 47 (21.28%)	0 / 2 (0.00%)	4 / 13 (30.77%)
occurrences all number	0	2	0	3	1	3	1	1	3	2	1	1	0	3	1	0	0	0	2	1	1	11	10	0	4
Dehydration
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	2 / 38 (5.26%)	3 / 47 (6.38%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	1	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0	1	0	0	1	2	3	0	1
Hyperglycaemia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	3 / 7 (42.86%)	0 / 3 (0.00%)	0 / 5 (0.00%)	2 / 3 (66.67%)	2 / 38 (5.26%)	3 / 47 (6.38%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	3	0	0	2	2	3	0	0
Hyperkalaemia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	3 / 38 (7.89%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	3	2	0	0
Hypoalbuminaemia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	2 / 10 (20.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	2 / 5 (40.00%)	1 / 3 (33.33%)	2 / 38 (5.26%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	2	1	0	2	1	2	1	0	0
Hypocalcaemia
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	2 / 10 (20.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	2 / 38 (5.26%)	2 / 47 (4.26%)	0 / 2 (0.00%)	1 / 13 (7.69%)
occurrences all number	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	2	2	0	1
Hypokalaemia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	2 / 8 (25.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	1 / 6 (16.67%)	0 / 2 (0.00%)	1 / 4 (25.00%)	1 / 3 (33.33%)	2 / 3 (66.67%)	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)	1 / 5 (20.00%)	1 / 3 (33.33%)	3 / 38 (7.89%)	7 / 47 (14.89%)	0 / 2 (0.00%)	3 / 13 (23.08%)
occurrences all number	0	0	0	0	0	2	0	0	0	1	1	0	1	1	2	0	1	0	1	1	1	3	7	0	3
Hypomagnesaemia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 7 (14.29%)	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	1 / 6 (16.67%)	0 / 2 (0.00%)	0 / 4 (0.00%)	2 / 3 (66.67%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)	2 / 3 (66.67%)	4 / 38 (10.53%)	9 / 47 (19.15%)	0 / 2 (0.00%)	2 / 13 (15.38%)
occurrences all number	0	0	0	1	1	0	0	0	0	1	1	0	0	2	0	0	1	0	1	0	2	4	9	0	2
Hyponatraemia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	2 / 7 (28.57%)	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 4 (0.00%)	3 / 10 (30.00%)	1 / 7 (14.29%)	2 / 3 (66.67%)	0 / 5 (0.00%)	1 / 3 (33.33%)	3 / 38 (7.89%)	3 / 47 (6.38%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	2	1	0	0	0	0	1	0	0	1	1	0	0	3	1	2	0	1	3	3	0	0
Hyperuricaemia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Hypovolaemia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Iron deficiency
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Hypophosphataemia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 10 (10.00%)	2 / 7 (28.57%)	0 / 3 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	2	0	0	1	0	1	0	0
Fluid retention
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hypercalcaemia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	2 / 47 (4.26%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
Hypoglycaemia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Hyperalbuminaemia
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Metabolic acidosis
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 38 (2.63%)	0 / 47 (0.00%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Type 2 diabetes mellitus
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 10 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 38 (0.00%)	1 / 47 (2.13%)	0 / 2 (0.00%)	0 / 13 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0

More information

Top of page

Were there any global substantial amendments to the protocol? Yes

26 Aug 2013

• To change cycle length from 28 to 21 days to align with standard chemotherapy cycle duration • To revise the definition of DLT • To add survival follow-up assessment for all subjects • Part A: To add cisplatin to the gemcitabine dose escalation after the initial gemcitabine escalation in order to determine the appropriate doses of M6620, cisplatin, and gemcitabine for Part C1 • Part B: To add a cisplatin-only escalation in order to determine the appropriate doses of M6620 and cisplatin for Part C2 • Part C: To expand Part C to 3 parts (Part C1 in NSCLC, Part C2 in TNBC, and Part C3 in SCLC)

26 Nov 2013

To revise the definition of DLT • Part C: To delete urinalysis on Days 3 and 9 • Parts C1, C2, and C3: To reduce the number of PK samples • Part C2: To exclude any prior platinum therapy for breast cancer in any setting (EC2)

16 May 2014

• To clarify the definition of refractory disease (Part C3) • To clarify stopping rules for subjects with progression disease (PD) • Part C3: To revise EC2 to exclude subjects who have not received at least 1 cycle instead of 2 cycles of prior platinum-based chemotherapy for SCLC • To allow preparation of gemcitabine and cisplatin per institutional practice • To update all timed assessments including PK and biomarkers to coincide with the actual end of infusion and allow for sample collections relative to the end of infusion • To update acceptable PK sampling windows • To update SAE reporting information

12 Jun 2014

• To remove the restriction on subjects receiving treatment with medications that are mainly metabolized by CYP3A4 as M6620 is not a potent inhibitor or inducer of Cytochrome P450(CYP) 3A and the probability of M6620 impacting such concomitant medications is low (EC14) • Part C3: To exclude subjects who had not received at least 1 cycle (rather than 2 cycles) of prior platinum-based chemotherapy for SCLC

13 Aug 2014

• To remove the restriction on treatment duration for subjects who appear to tolerate and respond to treatment for future subjects who may have potential clinical benefit from extended therapy • To expand the pretreatment window for safety laboratory assessments to 3 days before dosing • To allow Cycle 1 Day 21 assessments to be performed on Cycle 2 Day 1

08 Dec 2014

• To modify language to allow escalation of chemotherapy doses prior to escalation of M6620 to 200 mg/m^2 if exposures to M6620 exceed the predicted efficacious exposures at lower doses • To prevent pruritus by adding a rationale for management of potential infusion reactions, providing additional guidance for prevention, extending duration of M6620 infusion beyond 60 minutes, and updating the dilution volume for total doses of M6620 over 400 mg • Part C: To clarify that subjects who had received any prior platinum for squamous NSCLC except in the adjuvant or neoadjuvant settings are excluded

07 Apr 2015

• To revise the definition of DLT to exclude transient Grade 3 elevations in liver function tests (LFTs)

10 Jun 2015

• To revise the definition of DLT to exclude any grade of acute hypersensitivity reaction or the need to interrupt or discontinue treatment in the event of acute hypersensitivity • Part C: To exclude subjects receiving treatment with ototoxic or nephrotoxic medications that could not be discontinued >= 7 days before the first dose of study drug and for the duration of the study • Parts C1 and C2: To allow subjects who discontinue for reasons other than PD, who are nonevaluable for efficacy, or who discontinue due to PD before completing Cycle 1 to be replaced • Part C1: To redesign Part C1 to evaluate safety and efficacy of M6620 in combination with gemcitabine in approximately 30 subjects with advanced NSCLC who have received previous chemotherapy • Part C2: To redesign Part C2 to evaluate safety and efficacy of M6620 in combination with cisplatin in approximately 50 subjects with advanced TNBC • Part C3: To delete Part C3, which aimed to evaluate safety and tolerability of M6620 in combination with cisplatin and etoposide in subjects with relapsed or refractory SCLC

14 Dec 2015

• Part C1: To remove Prescreening • Part C2: To remove the requirement for >= 30 subjects to be androgen receptor (AR) negative

16 Feb 2016

• To clarify that MRI or bone scans may be used as an alternative to computed tomography (CT) scans for disease assessment but that the same technique should be used for assessment of response in an individual subject throughout the study • To exclude subjects diagnosed with Li-Fraumeni Syndrome or ataxia telangiectasia (EC 12) • Parts C1 and C2: To add starting doses for M6620/gemcitabine and M6620/cisplatin in Parts C1 and C2, respectively • Part C1: To allow enrollment of subject who had received an additional line of nonplatinum-based chemotherapy and those who had received prior gemcitabine for the treatment of non-small cell lung cancer (NSCLC) within 6 rather than 12 months (EC2) • Part C1: To enroll 10 subject without TP53 mutation or without ATM loss of expression and to remove the requirement for eligible subject to have documented radiologic progression • Part C2: To exclude the following subjects (EC2): Those who had received any prior platinum therapy for breast cancer within 6 months (rather than 2 years) of Screening; Those who had relapsed within 3 (rather than 12) months after completion of prior adjuvant or neoadjuvant chemotherapy; Those who had received any prior chemotherapy in the metastatic setting except for either a taxane or an anthracycline and 1 other nonplatinum-based chemotherapy • Part C2: To allow escalation of the dose of M6620 from 140 mg/m^2 to 210 mg/m^2 with 75 mg/m^2 cisplatin if initial doses of M6620 and cisplatin were tolerated in the first 5 of 6 subjects for 2 cycles • Part C3: To add a new Part C3, to evaluate the safety and efficacy of M6620 in combination with carboplatin in approximately 25 subjects with platinum-resistant advanced SCLC • Parts C1 and C2: Cycle 1 Day 9 PK sample removed

21 Aug 2017

• To remove the 5 mg/mL formulation of M6620

25 Jan 2018

• To add Part B2

Were there any global interruptions to the trial? No

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

None reported

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials

Clinical Trial Results: An Open-label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination with Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors

Trial information

Trial information

Subject disposition

Subject disposition

Baseline characteristics

Baseline characteristics

End points

End points

Primary: Parts A1, A2, B1: Number of Subjects with Treatment-Emergent Adverse Events (TEAEs)

Primary: Parts A1, A2, B1: Number of Subjects with Treatment-Emergent Adverse Events (TEAEs)

Primary: Parts A1, A2, B1: Number of Subjects with Clinically Significant Changes From Baseline in Laboratory Parameters

Primary: Parts A1, A2, B1: Number of Subjects with Clinically Significant Changes From Baseline in Laboratory Parameters

Primary: Parts A1, A2, B1: Number of Subjects with Clinically Significant Changes From Baseline in Vital Signs

Primary: Parts A1, A2, B1: Number of Subjects with Clinically Significant Changes From Baseline in Vital Signs

Primary: Parts A1, A2, B1: Number of Subjects with Clinically Significant Changes From Baseline in 12-Lead Electrocardiograms (ECGs) Findings

Primary: Parts A1, A2, B1: Number of Subjects with Clinically Significant Changes From Baseline in 12-Lead Electrocardiograms (ECGs) Findings

Primary: Part B2: Number of Subjects with Treatment-Emergent Adverse Events (TEAEs)

Primary: Part B2: Number of Subjects with Treatment-Emergent Adverse Events (TEAEs)

Primary: Part B2: Number of Subjects with Clinically Significant Changes from Baseline in Laboratory Parameters

Primary: Part B2: Number of Subjects with Clinically Significant Changes from Baseline in Laboratory Parameters

Primary: Part B2: Number of Subjects with Clinically Significant Changes from Baseline in Vital Signs

Primary: Part B2: Number of Subjects with Clinically Significant Changes from Baseline in Vital Signs

Primary: Part B2: Number of Subjects with Clinically Significant Changes from Baseline in 12-Lead Electrocardiograms (ECGs) Findings

Primary: Part B2: Number of Subjects with Clinically Significant Changes from Baseline in 12-Lead Electrocardiograms (ECGs) Findings

Primary: Parts C1, C2, C3: Number of Subjects with Treatment-Emergent Adverse Events (TEAEs)

Primary: Parts C1, C2, C3: Number of Subjects with Treatment-Emergent Adverse Events (TEAEs)

Primary: Parts C1, C2, C3: Number of Subjects with Clinically Significant Changes from Baseline in Laboratory Parameters

Primary: Parts C1, C2, C3: Number of Subjects with Clinically Significant Changes from Baseline in Laboratory Parameters

Primary: Parts C1, C2, C3: Number of Subjects with Clinically Significant Changes from Baseline in Vital Signs

Primary: Parts C1, C2, C3: Number of Subjects with Clinically Significant Changes from Baseline in Vital Signs

Primary: Parts C1, C2 and C3: Number of Subjects with Clinically Significant Changes from Baseline in 12-Lead Electrocardiograms (ECGs) Findings

Primary: Parts C1, C2 and C3: Number of Subjects with Clinically Significant Changes from Baseline in 12-Lead Electrocardiograms (ECGs) Findings

Primary: Parts C1 and C3: Percentage of Subjects with Objective Response (OR)

Primary: Parts C1 and C3: Percentage of Subjects with Objective Response (OR)

Primary: Part C2: Percentage of Subjects with Objective Response (OR) in Part C2 (TNBC) Who are Basaloid Subtype and BRCA1/BRCA2 Germline wild-type

Primary: Part C2: Percentage of Subjects with Objective Response (OR) in Part C2 (TNBC) Who are Basaloid Subtype and BRCA1/BRCA2 Germline wild-type

Secondary: Parts A1 and A2: Maximum Tolerated Dose (MTD) of M6620

Secondary: Parts A1 and A2: Maximum Tolerated Dose (MTD) of M6620

Secondary: Part A1: Maximum Observed Plasma Concentration (Cmax) of M6620

Secondary: Part A1: Maximum Observed Plasma Concentration (Cmax) of M6620

Secondary: Part A1: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of M6620

Secondary: Part A1: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of M6620

Secondary: Part A1: Apparent Volume of Distribution at Steady-state (Vss) of M6620

Secondary: Part A1: Apparent Volume of Distribution at Steady-state (Vss) of M6620

Secondary: Part A1: Apparent Total Body Clearance (CL) of M6620

Secondary: Part A1: Apparent Total Body Clearance (CL) of M6620

Secondary: Part A1: Apparent Terminal Half-Life (t1/2) of M6620

Secondary: Part A1: Apparent Terminal Half-Life (t1/2) of M6620

Secondary: Parts A1, A2 and B1: Percentage of Subjects with Objective Tumor Response (OR) as Evaluated by Response Criteria Evaluation in Solid Tumors (RECIST) 1.1

Secondary: Parts A1, A2 and B1: Percentage of Subjects with Objective Tumor Response (OR) as Evaluated by Response Criteria Evaluation in Solid Tumors (RECIST) 1.1

Secondary: Part B1: Maximum Tolerated Dose (MTD) of M6620

Secondary: Part B1: Maximum Tolerated Dose (MTD) of M6620

Secondary: Part B2: Maximum Tolerated Dose (MTD) of M6620

Secondary: Part B2: Maximum Tolerated Dose (MTD) of M6620

Secondary: Part B1: Maximum Observed Plasma Concentration (Cmax) of M6620

Secondary: Part B1: Maximum Observed Plasma Concentration (Cmax) of M6620

Secondary: Part B1: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of M6620

Secondary: Part B1: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of M6620

Secondary: Part B1: Apparent Volume of Distribution at Steady-state (Vss) of M6620

Secondary: Part B1: Apparent Volume of Distribution at Steady-state (Vss) of M6620

Secondary: Part B1: Apparent Total Body Clearance (CL) of M6620

Secondary: Part B1: Apparent Total Body Clearance (CL) of M6620

Secondary: Part B1: Apparent Terminal Half-Life (t1/2) of M6620

Secondary: Part B1: Apparent Terminal Half-Life (t1/2) of M6620

Secondary: Part B2: Maximum Observed Plasma Concentration (Cmax) of M6620

Secondary: Part B2: Maximum Observed Plasma Concentration (Cmax) of M6620

Secondary: Part B2: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of M6620

Secondary: Part B2: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of M6620

Secondary: Part B2: Volume of Distribution at Steady-state (Vss) of M6620

Secondary: Part B2: Volume of Distribution at Steady-state (Vss) of M6620

Secondary: Part B2: Apparent Total Body Clearance (CL) of M6620

Secondary: Part B2: Apparent Total Body Clearance (CL) of M6620

Secondary: Part B2: Apparent Terminal Half-Life (t1/2) of M6620

Secondary: Part B2: Apparent Terminal Half-Life (t1/2) of M6620

Secondary: Part B2: Percentage of Subjects with Objective Tumor Response (OR) as Evaluated by Response Criteria Evaluation in Solid Tumors (RECIST) 1.1

Secondary: Part B2: Percentage of Subjects with Objective Tumor Response (OR) as Evaluated by Response Criteria Evaluation in Solid Tumors (RECIST) 1.1

Secondary: Part C2: Percentage of Subjects with Objective Response (OR)

Secondary: Part C2: Percentage of Subjects with Objective Response (OR)

Clinical Trial Results:
An Open-label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination with Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors